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A major problem in the successful treatment of cancer is a loss in the effectiveness 
of chemotherapeutic drugs, such as cisplatin, due to development of drug resistance 
by tumour cells. Such resistance necessitates prescription of higher and potentially 
toxic concentrations of drugs. The side-effects of such treatments therefore both 
reduces the quality of patients’ life, and also contributes to the failure of effective 
chemotherapy. At present, the mechanisms by which such drug resistance operates 
are not fully understood. However, candidate markers for drug resistance are 
emerging, one of which is transglutaminase 2 (TG2). 
TG2 is a ubiquitous, multifunctional enzyme that is implicated in several pathological 
and physiological processes, including the regulation of cell division and cell death. 
Two TG2 isoforms, TG2-L and TG2-S, have been characterised. The overexpression 
of TG2 has been observed in various aspects of cancer, including the development 
of drug-resistance and cell survival. However, the amount to which TG2 contributes 
to the cellular environment of normal and drug-resistant cancer cells is poorly 
understood and is still controversial. In order to establish whether TG2 is directly 
involved in drug resistance mechanisms, TG2 gene expression at the mRNA level 
and protein levels was modulated in the hepatocarcinoma (HepG2) cell line, and the 
effects were measured, using RT-PCR, Western blotting, flow cytometry, confocal 
microscopy, and a range of assays for determination of TG2-specific enzymatic 
activity.  
This study provides evidence that TG2 expression and its associated transamination 
activity are inhibited during the initiation of apoptosis by cisplatin, an observation that 
was reversed by increasing the expression of TG2 following the treatment of cells 
with retinoic acid. Single-dose treatment of HepG2 cells with IC80 concentrations of 
cisplatin generated drug-resistant progeny cells that exhibited reduced TG2 
expression but increased enzyme activity, and this induced chemoresistance was 
accompanied by a reduced ability of cells to take up Alexa fluor 546/488-labelled 
cisplatin. Interestingly, treatment of cells with a classic TG2 inhibitor (cystamine), or 
treatment by TG2 mRNA silencing (siRNA), both reversed this effect and increased 
the level of uptake of fluorescent cisplatin in both parental and chemoresistant cancer 
cells.  
In conclusion, these results indicate that the presence of elevated levels of TG2 in 
hepatocellular carcinoma prevents and/or limits the entry of anti-cancer drugs. Thus, 
TG2 may represent a novel biomarker and possibly a therapeutic target for 
overcoming the chemotherapeutic resistance in hepatocarcinoma. 
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CHAPTER 1:  
1. GENERAL INTRODUCTION 
1.1 Background to the current study  
Despite the known roles of tranasglutaminase 2 in the development of cancer 
chemotherapeutic drug resistance, there is still more to discover regarding the 
implications of transglutaminase 2 in such mechanisms. Therefore, the overall aim of 
this study is to investigate the role(s) of transglutaminase 2 in the cellular uptake of 
the anti-cancer drug cisplatin in cisplatin–resistant compared to cisplatin-sensitive 
immortalised hepatocarcinoma (HepG2) cell lines.     
The proper equilibrium between cell death and proliferation is crucial for multicellular 
organisms to maintain healthy life. Cell death occurs in distinctive ways, i.e. through 
processes such as apoptosis, autophagy-associated cell death, necrosis, Wallerian 
degeneration, excitotoxicity, mitotic catastrophe, anoikis, and in the case of skin 
cornification (Green, 2011; Piacentini, et al., 2011). The end result of these processes 
is ultimately the removal from tissues of dead cells, usually under normal conditions, 
through the process of phagocytosis, and in this way the human body remains healthy 
(Green, 2011). Anything that disturbs these processes can make cells more or less 
responsive to abnormal conditions.  
Apoptosis is well-ordered and is achieved through the stimulation of specific 
intracellular pathways in response to various intracellular or extracellular death stimuli 
(Green, 2011). This “programmed cell death” performs many critical roles in 
physiological homeostasis and many diseases. It has important roles in the control of 
cancer, one of the deadly diseases of uncontrolled cell growth and proliferation, in 
which apoptosis is known to be deregulated (Hanahan and Weinberg, 2011). Some 
related mechanisms may cause cancer cells to become resistant to anti-cancer drugs 
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that are known to normally initiate apoptosis (Holohan, et al., 2013; Housman, et al., 
2014). One important component of the mechanisms that control apoptosis involves 
extensive intracellular protein cross-linking by transglutaminases (Fesus and 
Piacentini, 2002). The failure of this and other processes that affect plasma 
membrane and cytoskeletal structures may create cells that become resistant to 
chemotherapeutic drugs. 
Over the past three decades, the development of drug resistance in patients 
undergoing chemotherapy has been a major clinical challenge in cancer research. 
Several proteins have been identified that are involved in the mechanisms of drug 
resistance, and amongst these, transglutaminase 2 (TG2) has been identified as a 
putative tumour marker that is involved in multiple mechanisms related to cancer 
development and drug resistance. These include: gene regulation; tumour evasion of 
apoptosis; inflammation; and epithelial-mesenchymal transition (Mehta, Kumar and 
Im Kim, 2010; Budillon, Carbone, and D’Gennaro, 2013).  
There is limited knowledge regarding the role of TG2 in the cellular 
uptake/endocytosis of anti-cancer drugs such as cisplatin. Thus, this dissertation is 
focused on investigating the role of transglutaminase 2 in the cellular uptake of anti-
cancer drugs. The project developed drug resistant cells, in which elevated levels of 
transglutaminase 2 appeared to be associated with a reduced rate of trafficking of 
cisplatin across the plasma membrane. This study provides the first evidence to 
support a role for TG2 in the mechanism of cellular uptake of cisplatin. It also reports 
for the first time that cisplatin can cause direct inhibition of guinea pig liver 
transglutaminase activity and that TG2 transamination activity plays an important role 
in the mechanism of cisplatin induced cell death. It is thus hypothesised that cisplatin 
may act as an inhibitor of TG2 in vivo, and in this way may contribute to the induction 
of apoptosis in cancer cells.      
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1.2 General background to transglutaminase research  
Transglutaminase 2 was first isolated in 1957, from guinea pig liver extract, and 
characterised as a transamidating enzyme (Clarke, Sarkar and Waelsch, 1957). 
Following this discovery, it has been subsequently  shown that transglutaminases are 
not only present in mammals, but are present in many other diverse living organisms, 
e.g., unicellular organisms, invertebrates, plants, amphibians, fish and birds 
(Grenard, Bates and Aeschlimann, 2001).  
The transglutaminases (TGases; EC 2.3.2.13) are a peculiar family of structurally- 
and functionally-related enzymes that catalyse the intracellular and extracellular post-
translational modification of proteins by forming ү-glutamyl-ε-lysyl covalent bonds 
between free amine groups of protein- or peptide-bound lysine and ү-carboxamide 
groups of other protein- or peptide-bound glutamines, in a calcium-dependent manner 
(Mehta and Eckert, 2005; Nurminskaya and Belkin, 2012). TGases also catalyze the 
covalent incorporation of mono- or polyamines into proteins by deamidation and 
amine exchange with glutaminyl residues of proteins. In the absence of amine 
substrates, hydrolysis of glutamine results in the elimination of the amino group of 
glutaminyl residues by deamidation, leaving behind a glutamic acid residue (figure 
1.1) (Ichikawa, et al., 2004; Nurminskaya and Belkin, 2012). These enzymes are also 
capable of acting in reverse, and in this way can cleave pre-existing isopeptide bonds 
through isopeptidase activity, again in a calcium-dependent manner (Parameswaran, 
et al., 1997). However, in the absence of isopeptide cleavage, cross-links formed by 
transglutaminases are highly resistant to mechanical and chemical attack and 
normally can be only destroyed by proteolytic degradation of protein chains (Fesus 
and Piacentini, 2002). In summary, these enzymes appear to have multiple and 
important roles, as transglutaminase-mediated modification can change the function, 
stability, and immunogenicity of substrate proteins and so contributes to different 
diseases, including importantly with respect to this dissertation, cancer.  
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Figure 1.1 Transglutaminase catalysed reactions in the presence of 
calcium. 
(1) Protein cross-linking comes through the formation of ε -(ү-glutamyl)-lysine 
isopeptide bond between the lysine donor residue of one protein and the 
acceptor glutamine of another protein, (2) Transamination of amine into one 
of the active glutamine residue of the acceptor protein, (3) Deamidation of 
glutamine leaving behind glutamic acid (self generated diagram). 
 
1.3 The transglutaminase family of gene products  
Transglutaminases are broadly distributed in mammalian tissues and fluids and are 
categorised into at least five groups, centred on their biochemical properties. Some 
of the family’s genes are specifically expressed in single tissues, e.g., plasma; 
keratinocytes; prostate; and epidermis (Ichikawa, et al., 2004). In humans, nine 
transglutaminase genes have been found so far, and it appears likely that these 
enzymes are evolved from a series of single gene duplications (Eckert, et al., 2014). 
Eight members are catalytically active and all share an identical amino acid sequence 
at the active site. The family exception is Band 4.2 (an inactive erythrocyte membrane 
protein). Despite the presence of potential N-linked glycosylation sites and cysteine 
residues in these proteins, the members of the transglutaminase family normally lack 
glycosylation and disulphide bonds (Mehta and Eckert, 2005). All TGs, including 
those that are secreted (such as factor XIII), and those associated with membrane 
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(e.g. TG1) lack N-terminal hydrophobic sequences. Similarly, all members except the 
catalytically-inactive Band 4.2 require calcium for their catalytic activity (Eckert, et al., 
2005; 2014). 
1.3.1 Transglutaminase 1 
Transglutaminase 1 (TG1) is sometimes colloquially termed as ‘keratinocyte TGase’. 
Other names are ‘TGk’ and ‘particulate TG’. It is mainly expressed in the stratified 
squamous epithelial part of the skin, the upper digestive tract and in the lower female 
genital tract (Eckert, et al., 2014). The protein is membrane-bound and has a fatty 
acyl linkage in the NH2-terminal cysteine residue (Kim, Chung and Steinert, 1995; 
Klock and Khosla, 2012). In addition to responding to increased Ca2+ levels and 
proteolytic cleavage, interaction with tarazotene-induced gene 3 (TIG3) protein 
seems to regulate its catalytic activity (Eckert, et al., 2009). In addition, retinoic acid 
reduces expression, whereas phorbol ester induces TG1 mRNA and protein 
expression (Eckert, et al., 2005).  
The main function of TG1 in skin is cell envelope formation during keratinocyte 
differentiation (Mehta and Eckert, 2005). One study found that TG1 can covalently 
link synthetic analogue ω-hydroxyceramides to one of the glutaminyl residues of 
human involucrin by ester bond formation (Nemes, et al., 1999). It was also found 
that TG1 is involved in renal epithelial cell proliferation via activation of the signal 
transducer and activator of transcription 3 (STAT3) and protein kinase B (Akt) 
signalling pathway (Ponnusamy, et al., 2009; Zhang, et al., 2009).  Mutations in the 
TG1-encoding gene leads to the development of lamellar ichthyosis, an autosomal 
recessive hereditary disorder of cornification (Terrinoni, et al., 2012).  
Little is known about TG1 in apoptosis, but unpublished data from this study suggests 
that TG1 mRNA expression levels are decreased during cisplatin-induced apoptosis 
(Meshram, 2017).  
6 
 
1.3.2 Transglutaminase 2  
Transglutaminase 2 (TG2 or “tissue-transglutaminase”) is usually characterised as a 
multifunctional protein, as in contrast with the other transglutaminases, which appear 
to have narrower, more tissue-specific functions. It can be involved in diverse events 
in the living or dying cell (Fesus and Piacentini, 2002). It is also often termed ‘liver 
transglutaminase’, due to its abundance in hepatic tissue, and is one of the most 
extensively studied tissue-type transglutaminases, although its physiological role is 
presently not clearly understood (Mehta and Eckert, 2005). TG2, also referred to as 
TGc or Gh, is a 78 kDa enzyme, widely distributed in tissues and cell types (Fesus 
and Piacentini, 2002). It has recently been identified as having four differentially-
spliced isoforms in addition to the full length protein, including the short form, TG2-S 
or TGH, and TGH2 (Antonyak, et al., 2006; Tee, et al., 2010). In comparison to the 
full length TG2, TG2-S (or TGH) lacks the C-terminal 139 amino acids (amino acids 
548-687 are missing) and has altered terminal residues 539-548, whereas TGH2 
lacks the C-terminal 337 amino acids (amino acids 350-687 are missing) and has 
altered terminal residues 287-349. The other two variants, TG2v1 and TG2v2, have 
54 and 25 amino acids in the C-terminal divergent form of the full length protein 
respectively (Lai, et al., 2007; Klock and Khosla, 2012; Kojima, Kuo and Tatsukawa, 
2012).  
Transglutaminase 2 (TG2) is a unique member of the transglutaminase family of 
enzymes. Apart from its cross-linking role, TG2 is a GTPase and ATPase - capable 
of hydrolysis of GTP and ATP respectively - in a calcium-independent manner. It also 
acts as a G (Ghα) protein for G Protein Coupled Receptor (GPCR) signalling 
(Achyuthan and Greenberg, 1987; Singh, Erickson and Cerione, 1995; Chen, et al., 
1996; Iismaa, et al., 1997; Baek, et al., 2001; Lorand and Graham, 2003).  
7 
 
In the filarial parasite dirofilaria immitis, Chandrashekhar, et al., (1998) revealed the 
protein disulphide isomerase (PDI) activity of TG2. PDI activity catalyses disulphide 
bond formation in proteins via cysteine residues. 
A recent study by Mishra et al showed that TG2 has an intrinsic kinase activity, and 
is capable of phosphorylating proteins. Later, it was reported that TG2 kinase activity 
has roles in the nucleus, where it contributes to apoptosis by phosphorylating p53 
and retinoblastoma proteins. It also helps in regulating chromatin structure and 
functions by modifying histones (Mishra and Murphy, 2004; 2006; Mishra, et al., 2006; 
Mishra, Melino and Murphy, 2007).    
Transglutaminase 2 has non-enzymatic activities e.g. TG2 works as an adaptor 
protein during cell signalling. In the nucleus, TG2 interacts with α3-importin, whereas 
in the cytoplasm TG2 interacts with Phospholipase Cδ1 (PLCδ1), protein kinase A 
(PKA) anchor protein 13 (AKAP13), 14-3-3 proteins, breakpoint cluster region protein 
(Bcr), and ras-related C3 botulinum substrate 1 (Rac1). In the extracellular membrane 
(ECM) TG2 interacts with fibronectin, and angiocidin and endostatin, and on the cell 
surface TG2 not only interacts with transmembrane receptors, like integrins, GPCR, 
G protein-coupled receptor 56 (GPR56), platelet-derived growth factor receptor 
(PDGFR), syndecan-4, low density lipoprotein receptor-related proteins (LRP)-1 and 
5/6, but also directly binds to matrix metalloproteinase 2 (MMP2). TG2 also directly 
interacts with milk fat globulin EGF factor 8 (MFG-E8) protein during bridge formation 
between apoptotic target cells and macrophage β3 integrins (see review of 
Nurminskaya and Belkin, 2012). It seems that TG2 contributes in many biological 
processes, much more than the other transglutaminases and is the focus of this study.  
1.3.3 Transglutaminase 3    
Transglutaminase 3 (TG3) is a 77 kDa enzyme, located on 20q11-12 chromosome, 
and is also known as epidermal transglutaminase. It is mostly present in the 
epidermis, hair follicle and brain. Other names are ‘TGE’, ‘callus TG’, ‘Hair follicle TG’ 
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and ‘bovine snout TG’. Increased Ca2+ levels regulate its catalytic activity, and TG3 
mRNA expression (Klock and Khosla, 2012; Eckert, et al., 2014), and like TG2, TG3 
also has the potential to hydrolyse GTP. TG3 cross-links trichohyalin and keratin 
intermediate filaments to harden the inner sheath of hair, which is needed for hair 
fibre morphogenesis. The main function of TG3 in the human body is to form the cell 
envelope during the latter stages of differentiation in the epidermis and hair follicle, in 
order to protect tissues from dehydration, abrasion and infection. However, the exact 
mechanism for cell envelope formation is not clearly understood (Mehta and Eckert, 
2005; Eckert, et al., 2009; 2014).  
A recent study in male “Anopheles gambie” mosquitoes by Le et al., showed that TG3 
contributes to the coagulation of seminal fluids by cross-linking “Plugin” protein (Le, 
et al., 2013). Dermatitis herpetiformis, a skin disease, is caused by TG3 
autoantibodies (Sardy, et al., 2002). TG3 expression is found to be down-regulated 
in head and neck squamous cell carcinoma and in laryngeal carcinoma (Mehta and 
Eckert, 2005).   
1.3.4 Transglutaminase 4  
Transglutaminase 4 (Tgase-4, TG4), is also known as ‘prostate transglutaminase’, 
because of its unique expression in the prostate gland. It is also found in prostatic 
fluid and seminal plasma. Recently, its presence was found in human saliva, and in 
the vena cava and aortic smooth muscle of mice (Johnson, et al., 2012; Perez, et al., 
2013; Eckert, et al., 2014). The TG4 variant has been found in four different isoforms: 
TG4-L; -M (-M1 and –M2); and –S, in benign prostate hyperplasia and prostate cancer 
(Cho, 2010a; 2010b). In combination, retinoic acid and androgen treatment regulate 
the transcriptional expression of TG4 in human prostate cancer cells (Fujimoto, et al., 
2009; Rivera-Gonzalec, et al., 2012). 
The main role of TG4 in rodent biology is the copulatory plug formation in the female 
genital tract, and in suppression of sperm antigenicity of male rodents. The TGM4 
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knockout mouse study shows that presence of TGM4 is necessary for normal male 
fertility (Cho, 2010b; Dean, 2013). Some evidence is available which suggests that 
TG4-expression is intrinsically linked to the activation of hepatocyte growth factor-
like/macrophage-stimulating protein (HGF-L/MSP) receptor [also known as RON 
(Recepteur d’Origine Nantais)], which contributes to the increased cell motility in TG4-
expressing cells (Jiang, et al., 2010). The enzyme is also involved in cell-matrix 
adhesion, epithelial-mesenchymal transition and invasiveness in prostate cancer 
cells (Davies, et al., 2007; Jiang, et al., 2009; 2013; Cao, et al., 2013).  
1.3.5 Transglutaminase 5 
Transglutaminase 5 (TG5) is mainly expressed in foreskin keratinocytes, the epithelial 
barrier lining, and skeletal muscle cells. This variant has been shown to exist in three 
alternatively spliced isoforms: delta-3; delta-11; and delta3delta11 (Candi, et al., 
2001). Acetylation of TG5 occurs at the N-terminal end (Candi, et al., 2004). Phorbol 
ester treatment activates endogeneous TG5 and causes it to localise with vimentin 
intermediate filaments (Rufini, et al., 2004). GTP and ATP both inhibit TG5, whereas 
calcium activates its protein cross-linking activity. Full length Transglutaminase 5 
specifically cross-links loricrin, involucrin, and small proline-rich proteins in the 
epidermis (Candi, et al., 2001). Apart from the cornified cell envelope formation of 
keratinocytes, TG5 overexpression has been shown to be involved in Hek293 cell 
death (Cadot, et al., 2004). Missense mutations in TGM5 gene, at T109M and G113C, 
lead to the formation of the acral peeling skin syndrome (Cassidy, et al., 2005).      
1.3.6 Transglutaminase 6 
Transglutaminase 6 (TG6) is mostly expressed in testis and lung and to some extent 
in the brain of mice and is also called transglutaminase Y, TGy. It is also expressed 
in a human carcinoma cell lines with neuronal characteristics, where it is catalytically 
activated after proteolytic cleavage of the proenzyme (Eckert et al., 2014). Like TG3 
the main function of TG6 appears to be in cell envelope formation in the epidermis 
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and the hair follicle. Recently, TG6 antibodies have been found in the autoimmune 
disease familial-ataxia (Thomas, et al., 2013).    
1.3.7 Transglutaminase 7 
Little research has been carried out on Transglutaminase 7 (TG7), but it appears that 
it is found in the testes, lungs, and brain (Mehta and Eckert, 2005). In breast cancer 
patients, normally low TG7 mRNA expression level was seen to be increased with 
severity of disease suggesting a relationship with node involvement and patient 
outcome (Jiang, et al., 2003).   
1.3.8 Factor XIIIa 
Factor XIIIa is an important component of the blood coagulation system, found in 
blood plasma. It is also found in astrocytes, platelets, macrophages, the placenta, 
synovial fluid, the eyes, the heart, chondrocytes, dermal dendritic cells, and the 
osteoblast lineage. It is activated from a zymogen form, as the A subunit of a 
heterotetramer. Transforming growth factor-β, interleukin-1β and myeloid-enriched 
factors (GATA-1 and Ets-1) have all been shown to induce factor XIIIa gene 
expression (Johnson, et al., 2001; Klock and Khosla, 2012; Eckert, et al., 2014). 
The primary role of factor XIIIa catalytic activity is stabilisation of fibrin clots during 
blood coagulation, through cross-linking of proteins and formation of cross-links 
between fibrin monomers, in the presence of calcium (Nikolajsen, et al., 2014). 
Tridegin, on the other hand, inhibits factor XIIIa activity (Finney, et al., 1997).  
Factor XIIIa, in addition to TG2, is involved in chondrocyte hypertrophic differentiation, 
in a manner that is not reliant upon transglutaminase catalytic activity (Johnson, Rose 
and Terkeltaub, 2008).  It is also involved in autocatalytic cell death, inflammation, 
matrix secretion and deposition of proteins in osteoblasts, bone synthesis, 
hypertension, vascular permeability and angiogenesis. Mutations in Factor XIIIa or 
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deficiency cause impaired wound healing and bleeding problems (Nurminskaya, et 
al., 1998; Sane, Kontos and Greenberg, 2007; Jallad, et al., 2011).  
1.3.9 Erythrocyte membrane protein band 4.2 (Band 4.2)  
Band 4.2, also known as ‘ATP-binding erythrocyte membrane protein ’, is 
predominantly expressed on the membrane of erythrocytes, foetal liver, bone marrow 
and spleen. It is catalytically inactive compared to other members of Tgase, because 
of a Cys → Ala substitution of the catalytically active cysteine in the active site (Mehta 
and Eckert, 2005; Eckert, et al., 2014). Exon I is known to be alternatively spliced into 
two isoforms. It is essential for correct assembly of the red blood cell (RBC) 
membrane skeleton and in maintaining the stability and integrity of RBC by directly 
interacting with spectrin. Band 4.2 binds to the erythrocyte anion channel and acts as 
support: as an attachment point between the membrane skeleton and the lipid bilayer. 
Deficiency of protein band 4.2 in RBCs cause anemia, e.g., a study on Japanese 
recessive spherocytic elliptocytosis patients suggested that protein band 4.2 
expression was completely absent in these patients (Korsgren, et al., 1990; Sung, et 
al., 1990; 1991; Mandal, Moitra and Basu, 2002), resulting in anemic pathology. 
1.4 Structural and functional relationship in TG2  
Implications for the multifunctional roles of TG2 can be found by consideration of its 
primary, secondary and tertiary structure. Structurally, TG2 contains four domains: an 
NH2-terminal β-sandwich; a catalytic core; and two COOH-terminal β-barrels (figure 
1.2A) and each domain has a specific role.  
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Figure 1.2 Primary structure of TG2  
(A) Structural representation of TG2 domains, (B) representation of TG2 
domains in open and closed form. Calcium binding opens TG2 domains that 
makes TG2 catalytically active whereas GTP binding closes and makes TG2 
catalytically inactivate. NT = amine terminal β-sandwich; Cc = catalytic core; 
β1 = β-barrel 1; β2 = β-barrel 2 (diagram adapted from Piacentini, et al., 2011).      
 
The catalytic core of TG2 contains cysteine proteases (Cys-277, His-335, and Asp-
358), and is essential for transglutaminases’ catalytic activity, with a binding site for 
calcium, and two conserved tryptophan residues (W241 and W332), which are 
necessary for TG2 activity, as these residues stabilize the thiol-intermediates formed 
during catalysis. The X-ray crystal structure of human TG2 has been solved, at 2 Å 
resolution, by Pinkas and group (2007) (figure 1.3). In the presence of calcium, TG2 
opens its conformation, whereas in the presence of high ratios of GDP/GTP, it closes 
its catalytic site (figure 1.2B) (Pinkas, et al., 2007). The catalytic core possesses a 
BH3 (Bcl-2 homology 3) binding domain, which has binding site for the Bcl-2 protein 
family, involved in cell cycle regulation. The catalytic domain also contains a binding 
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site for nuclear localisation signals (NLS1), which contribute to its localisation during 
apoptotic death of cells by cross-linking cellular proteins (Peng, et al., 1999; Liu, 
Cerione and Clardy, 2002; Murthy, et al., 2002; Rodolfo, et al., 2004; Gundemir, et 
al., 2012). The binding of cofactors plays crucial roles for TG2, as this determines 
whether TG2 plays enzymatic or non-enzymatic roles, and like calcium binding, opens 
the conformation and allows TG2 to perform its catalytic function. On the other hand, 
binding of GTP/GDP closes TG2 conformation, which allows TG2 to participate in cell 
signalling pathways (Piacentini, et al., 2011).  
The first C-terminal β-barrel contains binding sites for GTP and GDP, and is only 
found in TG2 and TG3, whereas other members of TG family lack GTP/GDP binding 
site(s). These two guanine nucleotide cofactors modulate transamidase activity. The 
second C-terminal β-barrel contains a binding sites for phospholipase C (PLCδ), 
which allows TG2 to function in the pro-inflammatory pathway, and a second binding 
site for nuclear localization signal (NLS2) (figure 1.2A).  
A NH2-terminal β-sandwich domain contains a fibronectin/integrin binding site, which 
is crucial during cell adhesion and extracellular matrix organisation (figure 1.2A). A 
recent study has shown that TG2 also has a binding site for heparin, which influences 
the adhesive function of TG2 (Jacob, et al., 2012).  
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Figure 1.3 Conformational changes in the structure of transglutaminase 2.  
(A) GDP/GTP bound TG2, which represents the closed form (catalytically inactive), 
(B) Inhibitor bound TG2, which represents the open form but catalytically inactive as 
the inhibitor is bound to catalytic site, (C) Combination of both (Pinkas, et al., 2007). 
 
1.5 Transglutaminase 2 and its substrates  
Transglutaminase 2 (TG2) post-translationally modifies proteins; these modified 
proteins may change their functions and behave in a different manner from their 
unmodified states. TG2 modifies proteins only if they have specific substrate 
characteristics around a particular reactive glutamine residue in the primary amino 
acid sequence; the reactive glutamyl- and lysyl- residues must be accessible and 
should not be surrounded by certain residues, which are considered to be 
discouraging factors (Table 1.1) (Coussons, et al., 1992a; Csosz, et al., 2008). 
However, despite tremendous efforts, the exact molecular selectivity of TG2 towards 
its substrate is still not fully characterised.  
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Table 1.1 Charged side chains that can act as a discouraging factor in the 
transglutaminase-catalysed reaction. 
The presence of an asterisk (*) at a position relative to the glutamine (at posi tion 0) 
indicates that the charged side chain can act as a discouraging feature. Positive 
charges (Lys/Arg) and Negative charges (Asp/Glu) (adapted from Coussons, et al. 
1992a). 
 
Position                             -5        -4      -3     -2     -1     0     +1      +2    +3    +4     +5 
Positive charges                                                              
     Type A substrates          *                                          Q      *        *       *      *       *   
     Type B substrates                                                      Q      *                       * 
Negative charges  
     Type A substrates                      *                               Q                                *       * 
     Type B substrates                                *                     Q 
 
Many researchers have attempted to characterise TG2 substrates on the basis of 
amino acid sequences around the glutamine residue in the primary structure of 
protein substrates and it has been suggested that substrates may be divided broadly 
into two types (type A – which possess little ordered structure, and type B – which 
possess ordered structure, around the glutamine residue) (Coussons, et al., 1992a; 
Csosz, et al., 2008). As a result of such research, the number of potential substrate 
proteins for TG2 was recently reported to be 155 (see appendix II). The full database 
of TG2 substrates can be found in the “Transdab wiki database’’ (Csosz, Mesko and 
Fesus, 2009).  
Many proteins are substrates of TG2, e.g., Bcr, Rac1, fibronectin, and angiocidin, 
where they are enzymatically modified by TG2 (transamidation/cross-linking activity), 
whereas other proteins that bind noncovalently to TG2 are modulated but not 
enzymatically modified by TG2, e.g., integrins, PDGFR, MMP2 (Nurminskaya and 
Belkin, 2012).  
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1.6 The distribution and functions of TG2 in different cell 
compartments  
TG2 was initially thought to only act as a cytoplasmic protein. Later, it was found that 
TG2 is localised extracellularly, as well as intracellularly. Its occurrence is now known 
to be spread between the cell surface, plasma membrane, cytosol, nucleus, 
mitochondria, endolysosomes, and in the extracellular matrix (ECM) (Lorand and 
Graham, 2003; Zemskov, et al., 2006; Malorni, et al., 2008; Gundemir and Johnson, 
2009a; Park, Choi and Ha, 2010; Nurminskaya and Belkin, 2012).   
1.7 Regulation of TG2 expression and activation 
TG2 expression and activation is dependent on cellular physiological conditions. As 
a multifunctional protein that is present ubiquitously in the extracellular, as well as the 
intracellular, environment, TG2 expression and activation must be tightly regulated 
(Gundemir, et al., 2012). Under some physiological conditions, TG2 activation is 
necessary, whereas in other conditions deactivation is crucial.  
 
Figure 1.4 Activation and regulation of TG2 gene expression (TGM2) by 
various factors at different elements   
Regulatory elements of human TG2 gene expression. Elements identified so far that 
activates TG2 are shown in DNA at various positions. Retinoic acid response 
elements: RRE-2 (-1731), RRE-1 (-1720), glucocorticoid response element: GRE (-
1399), Nuclear factor κB response element: NF-κB (-1338), Interleukin-6 response 
element: IL-6 (-1190), Tumour growth factor-β1: TGF-β1 (-900), activator protein-2: 
AP-2 (-634), Hypoxia response element: HRE (-367), activator protein-1: AP-1 (-183), 
CAAT box (-96), GC box: Sp1 binding motifs (-54, -43, +59, +65), TATA box (-29), 
Nuclear factor-1: NF-1 (+4, +12). (diagram adapted from Gundemir et al., 2012).  
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TGM2 gene expression is controlled at the level of transcription, the gene having four 
Sp1 binding sites that are responsible for human promoter activation (Lu, et al., 1995; 
Griffin, Casadio and Bergamini, 2002). As it is a multifunctional protein, the TG2 
promoter is very sensitive to disturbance in the cell environment and activates very 
quickly upon binding of various activators (figure 1.4). 
One of the best known activator types are retinoids (i.e., retinoic acid and its 
derivatives). In the mouse, retinoid-dependent TG2 gene expression is mediated 
through a versatile tripartite retinoid response element, which is located in the 
promoter, 1.7 kb upstream from the transcription start site. The same position is 
responsible for human TG2 gene activation (Nagy, et al., 1996). Other activators are 
transforming growth factor-beta1 (TGF-β1), nuclear factor-kappaB (NF-kappaB), and 
hypoxia-inducible factor-1 (HIF-1) (Mirza, et al., 1997; Ritter and Davies, 1998; Jang, 
et al., 2010). Tumour necrosis factor and inflammatory cytokines, such as interleukin-
1β and interleukin-6, can also activate TG2 (Suto, Ikura and Sasaki, 1993; Chen, et 
al., 2000). Recently, it was found that interferon-ү (IFN-ү) activates extracellular TG2 
in the coeliac intestine via a phosphatidylinositol-3-kinase dependent pathway 
(DiRaimondo, Klock and Khosla, 2012). Another study showed that bone 
morphogenic proteins (BMP2 and BMP4) inhibit tissue transglutaminase gene 
expression in MC3T3 E1 cells (Ritter and Davies, 1998).    
1.8 Cellular and physiological functions of transglutaminase 2 
(TG2) 
To elucidate the physiological roles of transglutaminase at the molecular level, it is 
clearly important to identify its physiological protein substrates and to clarify the 
relationship between transglutaminase modification of in vivo protein substrates and 
biological responses (Ichikawa, et al., 2004). Several transglutaminase substrates are 
involved in normal cellular functions, such as cell motility, extracellular matrix 
formation, cell adhesion, cell cycle, apoptosis, metabolism, cytoskeleton, signal 
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transduction, endocytosis, exocytosis, adhesion and migration, cell differentiation, 
cell growth and proliferation, and autophagy. On the other hand, these modified 
proteins may lead to abnormal activity and diseases (including coeliac sprue, 
neurodegenerative diseases, autoimmune diseases, cancer, metabolic and 
endocrinologic diseases) (Esposito and Caputo, 2004; Facchiano, Facchiano and 
Facchiano, 2006; Csosz, et al., 2008; Facchiano and Facchiano, 2009). TG2’s roles 
in these processes are described below.  
1.8.1 Role of TG2 in endocytosis (cellular uptake). 
Entry of many molecules into cells is often not passive, but can be dependent on 
specific mechanisms of membrane-associated cellular transport, including receptor 
mediated endocytosis (RME). Endocytosis can control an array of activities, including 
apoptotic clearance of dead cells, cell signalling, cell-cell interaction and antigen 
presentation, neuronal transmission and most importantly nutrient uptake (Mellman, 
1996). During endocytosis, several proteins are expressed on the surface of cell 
membranes, which assist in the process of membrane-transport; one such candidate 
protein is TG2. Initial recognition of TG2 as endocytic protein was made by Davies in 
1980 and subsequently, several lines of evidence have been reported to support a 
role for TG2 involvement in RME of α2-microglobulin, polypeptide hormones, and 
interleukin-8, in mouse peritoneal macrophages, and human erythrocytes (Davies, et 
al., 1980; Schrier and Junga, 1981; Ray and Samantha, 1996; Abe, et al., 2000).  
TG2 works as an ATPase, and this activity may have a role in transporting molecules 
across the plasma membrane. Some alterations in RME or other functions of TG2-
ATPase may also have implications for the reduced uptake of anticancer drugs (e.g. 
cisplatin) by chemoresistant cancer cells. However, more research is required to find 
out the link between TG2 and drug transporter proteins, where TG2 may act as an 
activator or deactivator of drug transporters, or may itself act as a drug transporter, 
or as a direct inhibitor of transport processes.    
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1.8.2 Role of TG2 in cell adhesion and migration  
TG2 works in collaboration with at least two classes of transmembrane cell-ECM 
adhesion receptor proteins, i.e., β1/ β3/ β5 integrins and syndecan-4, where its 
activity modulates cell adhesion via non-covalent binding (Verma and Mehta, 2007). 
Subsequently, these proteins interact with fibronectin, collagen, and vitronectin, thus 
strengthening cells’ adhesive properties and thus reducing the probability of 
metastasis in cancer (Nurminskaya and Belkin, 2012).     
1.8.3 Role of TG2 in cell cycle and proliferation  
The GTPase or ATPase activity of TG2 is one of the requirements for cell cycle 
progression through S phase to G2/M phase, and overexpression of TG2 has been 
shown to affect this progression (Nurminskaya and Belkin, 2012). A recent study by 
the Nadalutti group has shown that intracellular TG2 is required for cell proliferation. 
They inhibited TG2 gene expression by siRNA and observed that the endothelial cell 
number was reduced after the arresting cell cycle at G1 phase (Nadalutti, et al., 2011). 
TG2’s G-protein activity is found to mediate signalling by alpha-1β-adrenergic 
receptor, initiating Fas-induced hepatocyte proliferation in mice (Sarang, et al., 2005).     
1.8.4 Role of TG2 in autophagy  
Autophagy is a process of degradation of cytoplasmic components (including dead 
cells) within lysosomes, which is different from the endocytosis-mediated degradation 
process (Mizushima, 2007). TG2 inhibits autophagy induction by cross-linking beclin 
1, one of the key proteins during autophagosome formation (Luciani, et al., 2010; 
Grosso and Mouradian, 2012). Impaired autophagy promotes pathological conditions, 
one of which has been suggested to be Alzheimer’s disease (Salminen, et al., 2013).  
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1.8.5 Role of transglutaminase 2 in apoptosis and cell survival 
1.8.5.1 TG2 and apoptosis 
Apoptosis (programmed cell death) is one of the most important processes in multi-
cellular organisms, and is essential in the development and maintenance of the 
proper equilibrium of cell differentiation and cell death. Apoptosis occurs through the 
activation of several specific intracellular as well as extracellular pathways, when the 
cells encounter death stimuli (Green, 2011).  
Two main pathways have been characterised for the induction of apoptosis: (1) The 
external pathway, in which the cell receives and disseminates the signal coming from 
the external environment, by activating receptor-specific membrane proteins from the 
tumour necrosis factor (TNF) receptor family (TNFR), which work as “death 
receptors’’. The TNF ligand binds to the receptor TNF-R1, which activates 
conformational changes in the receptor. TNF then induces the activation of modulator 
proteins, Fas-associated death domain (FADD) and TNF receptor-associated death 
domain (TRADD), which form death-inducing signalling complex (DISC). The DISC 
complexes then activate caspase proteins, which ultimately execute the apoptotic 
process (Wajant, 2002). (2) The second main apoptosis pathway is the internal 
pathway, in which cells receive and disseminate the signal from the internal cellular 
environment. The most common signals from inside the cells are increased levels of 
reactive oxygen species (ROS), DNA damage, default protein response, and 
deprivation of growth factors. Once a cell suffers from these effectors, the 
mitochondria of the cell become perturbed, causing the release of pro-apoptotic 
proteins to the cytosol (Green, 2011). The release of pro-apoptotic factors and of 
antagonists of cytosolic anti-apoptotic proteins causes activation of Apoptotic 
protease activating factor-1 (APAF-1) complex, which ultimately activates caspase 
proteins. Caspase proteins activate a series of further caspases, finally disassembling 
the cell by proteolytic action, and by activating various apoptotic protein substrates, 
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including DNases (Green, 2011). A specific endonuclease then cleaves DNA into 
non-repairable fragments, and the cell is shrunk into cross-linked apoptotic body, 
which is ultimately engulfed and removed without the generation of an inflammatory 
response, by phagocytosis (Green, 2011).  
An early evidence of TG2 activation occurs following cellular depletion of the enzyme 
glutathione S-transferase (GST), during the early phases of apoptosis. This depletion 
occurs because of the functional inactivation of GST P1-1 by TG2-dependent 
polymerisation (Piredda, et al., 1999). For induction of apoptosis, the intracellular 
localisation and available transamidating activity of TG2 is clearly crucial (Piacentini, 
et al., 2011). 
The first direct evidence that the cytosolic form of TG2 acts as proapoptotic factor 
was achieved by transfecting cells with cDNAs coding for mutant (inactive) , or wild 
type TG2, the protein products of which were targeted to different compartments of 
cells. The inactivation of cross-linking activity of TG2 in the nucleus was shown to 
lead to a reduction in apoptosis, indicating the importance of TG2 effects on cell death 
(Piacentini, et al., 2011). 
Further proof of the involvement of TG2 in apoptosis derives from experiments that 
showed that dual leucine zipper-bearing kinase (DLK) was oligomerised by TG2, 
when cells were treated with the apoptotic stimulus calphostin- C (Hebert, et al., 
2000). Interestingly, the oligomerisation of DLK appears in early phases of apoptosis. 
The proapoptotic nature of TG2 was confirmed by conducting the studies on wild type 
DLK, where oligomerised DLK sensitizes cells to calphostin- C -induced apoptosis, 
but cross-linked DLK does not (Hebert, et al., 2000). A recent in vivo study showed 
that TG2 plays a role in alcohol-induced hepatocyte apoptosis by cross-linking 
nuclear specificity protein 1 (SP1)-transcription factor. Cross-linked SP1 inactivation 
results in a reduction of c-Met expression, which is necessary for hepatocyte cell 
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survival (Tatsukawa, et al., 2011; Kojima, Kuo and Tatsukawa, 2012). In Jurkat T 
cells, TG2 helps in apoptosis induction by modifying calcium homeostasis, via cross-
linking RAP1, a GTP-GDP dissociation stimulator 1 (Hsieh, et al., 2013).  
1.8.5.2 Anti-apoptotic roles of TG2 
Recent evidence suggests that TG2 plays a dual role in transformed cells, not only 
acting as proapoptotic factor but also as an antiapoptotic factor. It has been 
suggested that TG2 works as a switch between pro- and anti-apoptotic functions, 
depending on the environment as well as the genetic background of the cells 
(Piacentini, et al., 2011). The first evidence of TG2 acting as prosurvival factor came 
from the study of Oliverio, et al., (1997), where it was found that the modification of 
Retinoblastoma (Rb) protein by TG2 is necessary for cell survival (Oliverio, et al., 
1997). Pre-treatment of cells undergoing apoptosis with retinoic acid (RA) showed the 
blocking of degradation of Rb by the action of caspases, which are important inducers 
of TG2 during transcription (Oliverio, et al., 1999). It has also been shown that 
translocation of TG2 to the nucleus in some cases may antagonise apoptosis, though 
this phenomenon is at present controversial (Piacentini, et al., 2015).  
In TG2-expressing cells, phosphoinositide 3-kinase (PI3K) regulates the 
transamidating and GTP-binding activity, by inhibiting the cross-linking activity of TG2 
(Lin, et al., 2011). TG2 inhibits apoptosis in several tumour cell lines, by modifying 
caspase-3 and Nuclear Factor-kappa B (NF-kB) activity (Cao, et al., 2008; Jang, et 
al., 2010; Kumar and Mehta, 2012). TG2 protects HEK293 cells from calcium-
overloaded apoptosis, by reducing Bax protein levels, (one of the Bcl2 family protein 
involved in apoptotic induction) (Cho, et al., 2010). It also acts as a cytoprotector to 
H9c2 cells, in which it was overexpressed during protein kinase A- and protein kinase 
C-dependent cell survival pathways (Almami, et al., 2014). This suggests that TG2’s 
dual roles may be regulated by conformational changes in the TG2 protein structure, 
where GTP converts TG2 from an “open” cell death- stimulating form, to a “closed” 
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cell-survival form (figure 1.2B) (Gundemir and Johnson, 2009b; Piacentini, et al., 
2011).  
1.9 Transglutaminase 2 in diseases  
Transglutaminase 2 is involved in various disease pathologies, either in 
overexpressed or repressed states. To date, it has been reported to contribute to 
inflammation, autoimmune diseases, diabetes, occupational asthma, 
neurodegenerative diseases, and cancer. 
1.9.1 Inflammation  
TG2 is an activator of inflammatory mediators and has been shown to enhance the 
activity of phospholipase A2 isoform, by forming an isopeptide bond within the 
enzyme; as a result the biosynthesis of pro-inflammatory eicosanoids increases (Elli, 
et al., 2009).  
NF-kB, one of the central downstream mediators of inflammation in inflammatory 
bowel disease (IBD), is activated by TG2, which exerts inflammatory and anti-
inflammatory effects in immune cells and colonic epithelial cells respectively (Elli, et 
al., 2009). Aggregation and sequestration of the anti-inflammatory factor peroxisome 
proliferator activated receptor γ (PPARγ) by TG2 has also been shown to stimulate 
inflammation (Elli, et al., 2009; Luciani, et al., 2010; Oh, et al., 2011).  
Recently, TG2 antibodies have been found as one of the potential biomarkers in 
occupational asthma (OA), induced by low molecular weight agent, isocyanate (Hur 
and Park, 2015).   
1.9.2 Autoimmune diseases 
Coeliac disease is one of the best examples of a disease in which TG2 pathology is 
strongly implicated. This is a digestive system disorder, causing destruction of the 
small intestine by undigested rigid peptide fragments (Siegel and Khosla, 2007). The 
first sign of development of coeliac disease is generation of modified gluten peptides, 
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through deamidation of specific glutamine residues in gliadin by TG2, resulting in T 
cell stimulation. Later, these cells produce antibodies against TG2, which can used 
clinically as an early diagnostic marker of this disease (Fesus and Piacentini, 2002).   
TG2 is also associated with type 1 and type 2 diabetes (Porzio, et al., 2007; Maglio, 
et al., 2009; Salter, et al., 2012). Missense mutations in the TGM2 gene have been 
found in TG2 protein in patients with early onset type 2 diabetes, corresponding to 
amino acids at positions Met330Arg, Ile331Asn, and Asn333Ser. Further supportive 
evidence came from TG2 knock-out mice that were shown to express glucose 
intolerance and had impaired insulin secretion (Porzio, et al., 2007; Salter, et al., 
2012).        
1.9.3 Neurodegenerative diseases  
Huntington’s disease (HD) is caused by expansion of CAG (cytosine-adenine-
guanine) triplet repeats in the gene coding for huntingtin protein, which produces an 
expanded polyglutamine-containing abnormal huntingtin (HTT) protein 
(McConoughey, et al., 2010). TG2 mediates cross-linking of HTT protein, which 
aggregates in the nucleus of neuronal cells and results in cell death in the striatum 
and cortex. Several studies have shown that TG2 activity is increased in brain tissue 
in HD patients, and TG2 co-localization has been shown with HTT aggregates 
(Grosso and Mouradian, 2012).  
Alzheimer’s disease (AD) is caused by extensive formation of aggregated amyloid 
beta-(Aβ) containing senile plaques and cerebral amyloid angiopathy, and 
aggregated tau-containing neurofibrillary tangles. TG2 has been implicated as a 
factor involved in the formation of Aβ and tau protein aggregates, through its cross-
linking activity. TG2 also polyaminates tau protein in AD (Wilhelmus, et al., 2009; 
Martin, De Vivo and Gentile, 2011; Grosso and Mouradian, 2012). 
The pathology of Parkinson’s disease and dementia also feature damage of 
neurological cells by formation of α-synuclein aggregates in Lewy bodies, mediated 
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by TG2 cross-linking of α-synuclein protein (Verhaar, et al., 2011; Grosso and 
Mouradian, 2012).      
1.9.4 Transglutaminase 2 in cancer  
Cancer is one of the deadly diseases of uncontrolled cell growth and proliferation, 
responsible for many deaths worldwide. Currently, one of the major obstacles in 
combating cancer is a failure of chemotherapy due to development of drug resistance 
by cancer cells to novel chemotherapeutic drugs, which later results in tumour 
recurrence and multidrug resistance. There are different risk factors for the 
development of cancer, including mutagenic and toxic chemicals, infections, and 
environmental factors, which induce genetic and epigenetic changes, resulting in 
continuous activation of signalling events independent of growth factors (Eckert, et 
al., 2014). So far, ten hallmarks of cancer have been proposed. These include 
sustained proliferative signalling, evasion of growth suppressors, activation of 
invasion and metastasis, enabling replicative immortality, induction of angiogenesis, 
resistance to cell death, avoidance of immune destruction, tumour-promotion of 
inflammation, genome instability and mutation, and deregulation of cellular energetics 
(Hanahan and Weinberg, 2011) (figure 1.5). TG2 has been implicated in most of these 
hallmarks, mainly as a mediator protein, rather than through direct involvement.  
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Figure 1.5 The hallmarks of cancer  
Ten hallmarks of cancer cell are considered to be responsible to enable 
them to become tumourogenic. TG2 has been found to be involved in these 
hallmarks (self-generated diagram).    
 
 
1.9.4.1 TG2 in drug resistance 
Over the past three decades, drug resistance has become a major challenge in 
cancer chemotherapy. The mechanisms that cause cancer cells to become resistant 
to drugs have been under investigation, and several enzymes, proteins and genes, 
including TG2, have been identified as having roles in such processes. High levels of 
TG2 expression have been found in a wide variety of cancers (Verma and Mehta, 
2007). Surprisingly, TG2 silencing or TG2 enzymatic activity inhibition has reversed 
drug resistance in drug-resistant cancer cells to stress- or drug-induced apoptosis 
(Kim, et al., 2006; Kim, Park and Kim, 2009). 
One of several mechanisms that contribute to drug resistance appears to result from 
activation of nuclear factor-kappa B (NF-ᴋB), through the cross-linking and 
polymerisation of free IᴋBα, induced by TG2 (Lee, et al., 2004). Another mechanism 
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of drug resistance results from activation of EGFR via JNK and ERK pathway, 
induced by TG2 (Li, et al., 2011). The degradation of phosphatase PTEN by TG2 
results in the constitutive activation of the FAK/PI3K/AKT cell survival pathway and 
so contributes to drug resistance (Verma, et al., 2006; 2008). A further mechanism of 
drug resistance occurs through depletion of nucleoplasmin by TG2 cross-linking 
activity (Park, et al., 2009).   
Epithelial to mesenchymal transition (EMT) is the conversion of an epithelial cell 
phenotype to a mesenchymal cell phenotype. Recently, the presence of TG2 has also 
been found during the conversion of epithelial cell to mesenchymal cell, which later 
becomes resistant to anti-cancer drugs and metastasises to different parts of the body 
(Agnihotri, Kumar and Mehta, 2013).  
 
Figure 1.6 The hallmarks of drug-resistance   
TG2 has been found to be involved specifically in some of the known 
hallmarks of drug-resistance, e.g., having roles in reduced apoptosis and 
altered cell proliferation, possibly controlled by TG2 modifying key 
mechanism-related proteins (self generated diagram).   
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So far, the role of TG2 has been strongly associated with reduced apoptosis and the 
altered cell proliferation that eventually leads cells to development of drug resistance. 
TG2 is involved in reduced apoptosis by specifically modifying apoptosis inducing 
proteins, e.g., Bax, Bim, Bad, DR5, and surviving; on the other hand, it is involved in 
altered cell proliferation by modulating the expression of proteins that are involved in 
cell survival pathways, e.g.,. NFkB, Bcl2, BclX1, EGF, JNK, ERK, AKT and FAK, 
leading cells to proliferate uncontrollably.           
Despite multiple lines of evidence that implicate TG2 involvement in drug resistance, 
the exact mechanism of TG2 induction during the drug resistance of cancer cells is 
not completely understood. Indeed, it seems likely that TG2 is involved in drug 
resistance because of its involvement in multiple pathways that regulate several 
hallmarks of drug-resistance (figure 1.6). 
1.10 Transglutaminase 2 inhibitors  
Although there is a known naturally-occurring inhibitor of factor XIII, no naturally-
occurring specific inhibitor of TG2 has so far been found. Some synthetic peptide 
inhibitors have proven effective, but these work only under specific conditions in vitro. 
Some inhibitors are available in synthetic peptide form (Siegel and Khosla, 2007). 
Thus, there is need to find specific TG2 inhibitor(s), which will inhibit TG activity 
without directly affecting key modulators of other cellular processes.    
Transglutaminase 2 inhibitors can be categorised into three classes, depending on 
their mechanism of inhibition. These three classes of inhibitors are 1) competitive 
amine inhibitors, 2) reversible inhibitors, and 3) irreversible inhibitors (Siegel and 
Khosla, 2007; Pinkas, et al., 2007).  
1.10.1 Competitive amine inhibitors  
Competitive amine inhibitors are those that compete with natural amine substrates 
for the TG2 active site, in a transamidation reaction. The substrate and inhibitor are 
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unable to bind to the active site at the same time, hence cross-links are formed 
between the natural glutamine and the inhibitor’s amine , instead of natural glutamyl 
TG2 substrate(s). Competitive inhibitors are often similar in structure to the natural 
substrates (Choi, et al., 2005; Siegel and Khosla, 2007).   
Some of the most commonly used and commercially available, chemically stable, and 
relatively non-toxic, competitive amine inhibitors of TG2 are cystamine, 
monodansylcadaverine, putrescine, cadaverine, and 5-(biotinamido)-pentylamine. 
Cystamine is probably the most used TG2 inhibitor, because it uniquely has multiple 
inhibition mechanisms, affecting disulphide bonds and maintaining sulphydryl 
containing residues in a reduced state (Siegel and Khosla, 2007).     
1.10.2 Reversible inhibitors 
Reversible inhibitors prevent enzyme activity by blocking substrate access to the 
active site without covalently modifying the enzyme; e.g., TG2 cofactors, like GTP 
and GDP, reversibly inhibit TG2 in vivo. In some cases, the ion Zn2+ reversibly inhibits 
TG2 activity by competing with Ca2+ for the binding site. Some GTP analogues can 
inhibit TG2 activity reversibly, for example, GTP?S and GMP-PCP (Pinkas, et al., 
2007; Siegel and Khosla, 2007).    
1.10.3 Irreversible inhibitors  
Irreversible inhibitors, also called suicide inhibitors, prevent enzyme activity by 
covalently modifying enzymes, thereby blocking the binding of substrate. Most of 
these inhibitors are designed to directly target cysteine in the catalytic site of TGs, 
and are often not found naturally, like other inhibitors (Siegel and Khosla, 2007).  
Iodoacetamide is one of the simplest irreversible TG2 inhibitors. It has been shown 
that iodoacetamide reacts with nucleophilic residues other than the active site 
cysteine. Another irreversible inhibitor of TG2 is 3-halo-4,5-dihydroisoxazoles, which 
is chemically and biologically suitable for inhibition (Choi, et al., 2005; Siegel and 
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Khosla, 2007). However, these inhibitors are not sufficiently strong enough to 
completely ablate the effects of TG2 and therefore may have been neglected by 
researchers.    
1.11 Use of cisplatin in Hepatocellular carcinoma  
Hepatocellular carcinoma (HCC) (liver cancer) is one of the primary liver malignancies 
and has been recorded as the 2rd most common reason for cancer-related deaths 
worldwide (Ashtari, et al., 2015). Chronic infection of the liver with Hepatitis B and C 
viruses (HBV & HCV) is the main cause of HCC development (Attwa and El-Etreby, 
2015; Ashtari, et al., 2015), whereas alcohol consumption, obesity, aflatoxin toxicity, 
diabetes and fatty liver acid are the secondary causes (Attwa and El-Etreby, 2015). 
Recent studies have also identified the stem cells of HCC which are supposed to be 
another cause for the recurrence of cancer, despite long term treatment with anti-
cancer drugs. Long-term survival has been found to be poor (Tomuleasa, et al., 
2010).   
 
Figure 1.7 Chemical structure of cisplatin. 
  
The platinum derivative cis-diaminedichloroplatinum (CDDP), best known as cisplatin 
(figure 1.7), is one of the most effective and currently-used anti-cancer drugs for 
patients affected by testicular, ovarian, head and neck, colorectal, bladder, lung, 
(Galluzzi, et al., 2014), and liver cancer (Song, et al., 2015). Over the last five years, 
the use of cisplatin in the treatment of advanced HCC has increased and shown 
several encouraging results. However, in many cases cisplatin response has 
relapsed after initial treatment and the tumour fails to respond, which results in 
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cisplatin resistance. To overcome this problem higher concentrations of cisplatin are 
recommended, which causes serious side effects, i.e. nephrotoxicity and ototoxicity 
(Ishida, et al., 2002). Therefore, understanding of specific mechanisms is crucial to 
overcome cisplatin resistance and improve the treatment.      
1.11.1 Mode of cisplatin action  
It is known that cisplatin cross-links DNA, and in this way inhibits DNA synthesis to 
induce apoptosis or to simply arrest the cell cycle (Gonzalez, et al., 2001; Qin and 
Ng, 2002; Zhang, Niu and Zhou, 2010). Cisplatin enters into the cellular environment 
by passing through the plasma membrane, to the cytoplasm, where it may come in 
contact with various proteins or enzymes, and then finally it enters the nucleus (figure 
1.8); the way cisplatin works in the body is not fully understood. For example, it is not 
always the case that simple arrest of DNA synthesis is sufficient in itself to induce 
apoptosis, as there are many other proteins that are involved in cisplatin-induced 
apoptosis (Dasari and Tchounwou, 2014). Cisplatin is in fact a non-specific drug and 
can bind to any molecules that contain nucleophilic sites, such as DNA, RNA, and 
proteins. Indeed, it has been suggested that cisplatin may initiate apoptosis by 
damaging cytoplasmic proteins (Gonzalez, et al., 2001).  
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Figure 1.8 Hydrolysis of cisplatin and its binding to different molecules (self 
generated diagram).  
 
1.11.2 Cisplatin resistance 
Cisplatin is mostly used for treatment of solid tumours, and for treating metastatic 
cancer. Development of cisplatin resistance in different cancers has shown that 
cancer cells have self-defence mechanisms pertaining to drug uptake. It appears that 
these self defence mechanisms arise from multiple epigenetic and genetic changes 
at the molecular and cellular level, including reduced accumulation of cisplatin, 
increased DNA damage repair, apoptosis inhibition, defective endocytosis and control 
of membrane transporters during cisplatin trafficking, changes in transcription factors, 
histone modification, and activation of EMT pathway (Shen, et al., 2010; 2012). It is 
also evidenced from drug-resistant cells that, during cisplatin entry, several proteins 
or enzymes interact with cisplatin and that this may reduce the cytotoxicity of cisplatin 
(Zhang, Niu and Zhou, 2010), and in this way may contribute to the development of 
drug resistance.    
1.11.2.1 General mechanisms of membrane transport for drugs  
Cells live by exchanging molecules with their environment. The exchange of 
molecules is controlled by the plasma membrane, which acts as a barrier to transit 
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molecules into and out of the cell. Entry of molecules into and out of the cell occurs 
through various membrane transport mechanisms. There are four main mechanisms, 
of which two are more important in the transport of drugs: 1) diffusion across the lipid 
bilayer of the membrane, and 2) carrier-mediated transport (Alberts, et al., 2013). 
Diffusion across the lipid bilayer is concentration gradient-dependent and transports 
molecules from high to low concentrations. Carrier-mediated transport occurs by 
passive transport, through channels or transporters, and by active transport through 
specific transporters that require energy (Alberts, et al., 2013) (figure 1.9). 
 
Figure 1.9 Mechanisms of membrane drug transports.  
(A) Simlpe diffusion - down concentration gradient, (B) Carrier-mediated transport: 
Passive transport - down concentration gradient; Active transport – against 
concentration gradient (self generated diagram). 
    
Emerging research indicates that TG2 is involved in drug resistance, but how it is 
involved and what roles it plays are still unsolved. The relationship between defective 
uptake of cisplatin, and overexpression/involvement of TG2 on the cell membrane or 
cytoplasm during cellular uptake of cisplatin and other anti-cancer drugs has been 
little studied so far. Therefore, this current study seeks to advance knowledge in this 
area, specifically focusing on the mechanisms of modulation of influx of anti-cancer 
drugs with relation to expression of TG2.     
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1.12 Aims of the current study  
So far, experimental evidence suggests that TG2 is an enigmatic enzyme, which 
appears to be ubiquitous, and is found in the extracellular matrix, cell surface, plasma 
membrane, cytosol, mitochondria, recycling endosomes, and nucleus, and that its 
subcellular localisation is an important determinant of its functions. However , the 
exact physiological role or roles of TG2 are still unclear. The aim of this research is 
therefore the following:  1) to investigate the association of TG2 with apoptosis and/or 
cell survival after cisplatin treatment in hepatocarcinoma HepG2 cell lines; 2) to 
investigate the relationship of TG2 with respect to development of cisplatin-resistance 
in HepG2 cell lines; 3) to investigate the role of TG2 in cellular uptake of cisplatin in 
cisplatin-resistant HepG2 cell lines; 4) to perform a preliminary investigation into the 
scale of modification and molecular characterization (at the level of determination of 
molecular weight) of cellular TG2 substrate protein(s) during the cellular uptake of 
dansylcadaverine in HepG2 cell lines.     
Collectively, this research provides more detail, concerning the role of TG2 in cancer 
and drug resistance and so may help to develop novel strategies for the use of TG2 
as a novel cancer biomarker and as a novel target for chemotherapeutic therapy.
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CHAPTER 2: 
2. MATERIALS AND METHODS 
2.1 Stock solutions’ preparation  
Cisplatin (2 mM): Stock solutions of 2 mM cisplatin were prepared in 18 mΩ ultrapure 
water under subdued light and stored in the dark at room temperature before use. 
Freshly-prepared cisplatin solution was used for every experiment, owing to its 
instability in aqueous solution. 
Retinoic acid (10 mM): Special precautions were taken during preparation of retinoic 
acid (RA) solutions, as it is sensitive to UV light, air and oxidizing agents. Preparation 
of 10 mM (3 mg/ml) RA in absolute ethanol was performed under subdued light and 
in a glove bag under an atmosphere of inert gas and stored at -20 oC. RA solutions 
were diluted with tissue culture medium prior to any treatments and used within two 
weeks. 
Cystamine (0.5 M): Stock solutions of 0.5 M cystamine were prepared in ultrapure 
water and stored at 4 oC.     
2.2 Cell lines and cell culture preparation  
The Hepatocellular carcinoma (HepG2) and Renal carcinoma (CAKI2) cell lines used 
in this study were procured from the European Collection of Cell Cultures (ECCC) 
(Sigma Aldrich, UK). Cell authentication was confirmed by comparison with online cell 
morphology.   
The HepG2 cells were cultured in RPMI 1640 culture medium (Life Technology, UK), 
fully supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma Aldrich, UK).  
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The CAKI2 cells were cultured in McCoy’s culture medium (Life Technologies , UK), 
fully supplemented with 10% (v/v) heat-inactivated foetal calf serum (FCS), 2 mM L-
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. 
The cell cultures were maintained in an incubator at 37 oC in the presence of a 
humidified 5% CO2 atmosphere and were kept free of mycoplasma contamination by 
adding Plasmocin, a commercially available antibiotic, during initial maintenance of 
cell cultures. Cells were observed on a regular basis and fed with fresh culture 
medium after every 2-3 days. Cell cultures were transferred to a new culture flask by 
trypsinization (0.1% trypsin plus 0.02% EDTA) once cells reached 90% confluence. 
Cell viability and cell counts were performed by trypan blue assay and handheld 
automated cell counter (Scepter Millipore, UK), respectively. Passage numbers 6-12 
were used for all experiments.    
2.2.1 Cell viability by trypan blue assay  
Cell viability was assessed by trypan blue assay; viable cells exclude trypan blue, 
whereas non-viable cells retain it. After trypsinisation, cell suspensions were diluted 
with culture medium and mixed with trypan blue dye (0.4% in phosphate buffered 
saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4)) 
in a ratio of 1:1. The mixture was incubated for 15 minutes at room temperature on 
a bench-top. Then, 10 µl of trypan blue-cell suspension were transferred to a 
hemocytometer chamber, with a cover-slip in place, and cells were observed, using 
an inverted phase contrast microscope.     
2.2.2 Cell passaging 
Cell passaging was performed once cells reached 90% confluence. The old culture 
medium was aspirated from the culture flask and cells were washed once with sterile 
PBS. Then, trypsin was added according to the size of culture flask (e.g. 1 ml/25 cm2, 
3 ml/75 cm2, and 6 ml/160 cm2) and incubated for 5-10 minutes at 37 oC, until cells 
detached from the bottom of the flask. After incubation, the trypsinization reaction was 
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stopped by adding the same amount of warm fully-supplemented culture medium. 
Then, cells were re-cultured in the new culture flask, at a ratio of 1:3 and incubated 
at 37 oC in the presence of a humidified 5% CO2 atmosphere.      
2.2.3 Cells cryopreservation   
Cells were cryopreserved in a freezing medium (90% RPMI 1640 culture 
medium/10% dimethylsulphoxide (DMSO)). Briefly, cells growing in a culture flask at 
90% confluence were collected by trypsinization and spun at 1000 rpm for 5 minutes. 
The cell pellet was gently broken up in freezing medium by slow pipetting up and 
down, and 1 ml of freezing medium, containing cells at 1x106 cells/ml, were 
transferred to several freezing vials, and then immersed in an isopropanol solution, 
within a “Mr. Frosty” container (Sigma Aldrich, UK), and incubated at -80 oC. After 24 
hours, all cryovials were preserved in liquid nitrogen at -196 oC in a hanging position.        
2.3 Single dose treatment method for the development of drug 
resistance cells   
Cisplatin resistant HepG2/cr cells were developed by a single dose treatment method, 
according to the guidelines described in McDermott, et al., (2014), with minor 
modifications. Approximately 1x106 cells were grown in a 75 cm2 culture flask at 37 
oC in the presence of a humidified 5% CO2 atmosphere. After 24 hours, cells were 
treated with freshly made 8 µM cisplatin, continuously, for 4 days. After incubation, 
cells were washed twice with warm culture medium and incubated in cisplatin-free 
culture medium for 4 weeks, changing the media after every 2-3 days. The surviving 
colonies were recovered by passaging and then frozen down in liquid nitrogen as 
described in section 2.1.3; the treatment was conducted in duplicate. Control flasks 
were left untreated, but were passaged alongside the treatment flasks. The cell 
colonies collected from the cisplatin-treated flasks were named HepG2/cr cells. The 
morphology of both cell lines was monitored using an inverted phase contrast 
microscope. Then, cells were exposed to 0-40 µM cisplatin for 24 and 48 hours, and 
drug sensitivity was tested, and compared to non-drug resistant parental cells.  
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2.4 Cell migration assay  
Cell migration assays were performed according to the method described by Liang 
(Liang, Park and Guan, 2007). Approximately 400,000 cells/well were grown in 12-
well culture plates for 24 hours. Then, media was removed and a horizontal scratch 
wound across the monolayer was created using a sterile 10 µl pipette tip. Cells were 
washed twice with fresh culture media and detached cells in the media were 
aspirated. Then, cells were inspected using an inverted phase-contrast light 
microscope, prior to incubation at 37 oC in a humidified 5% CO2 atmosphere for further 
observation.  
2.5 Cytotoxicity assay with the cell counting kit-8 
The cell counting kit-8 (CCK-8) assay is a colorimetric procedure, based on the ability 
of viable cells to reduce a yellow-coloured formazan dye. The assay utilises WST-8 
[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, 
monosodium salt] in conjugation with an electron mediator, 1-methoxy-5-
methylphenazinium methylsulphate, to assess cell viability.  
HepG2 and HepG2/cr cells were trypsinized and re-suspended in fresh culture 
medium at a concentration of 1x105 cells/ml. The cells were seeded into 96-well cell 
culture plates, at 10,000 cells per well, in a 100 µl volume of fully-supplemented RPMI 
1640 medium.  Blank control wells were filled with 100 µl fresh culture medium, with 
omission of the cells.  The cells were then grown for 24 hours at 37 oC, in the presence 
of a humidified 5% CO2 atmosphere. Following incubation, the culture medium was 
removed and 100 µl of fresh culture medium, containing freshly-prepared drugs, were 
added and samples were incubated prior to assay over defined time courses. At 
defined incubation times, 10 µl of the CCK-8 reagent were added directly to the cell 
cultures and incubated for another 4 hours at 37 oC in the presence of a humidified 
5% CO2 atmosphere.  The WST-8 formazan product was then measured at 450 nm 
using a monochromator-based multi-mode microplate reader equipped with Megalan 
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software (Sunrise, UK). The viable cell numbers were calculated according to the 
following formula:  
Viable cells (%) = [(OD450nm of Test – OD450nm of Blank) / (OD450nm of Control – OD450nm 
of Blank)] x 100    
The IC50 value is defined as the concentration of toxic agent required to reduce cell 
survival by 50%. All samples were assayed in triplicate, with a minimum of three 
independent experiments.  
2.6 Nuclear staining with DAPI  
HepG2 cells were grown on coverslips, in 6-well culture plates, in the presence of a 
humidified 5% CO2 atmosphere. After 24 hours, cells were treated or not-treated with 
a range of concentrations of cisplatin and incubated for a further 24 hours. After 
incubation, cells were washed briefly with 1x PBS. Then, samples of treated and non-
treated (control) cells were fixed and permeabilized with 4% formaldehyde/0.2 M 
sucrose, for 20 minutes, at room temperature, in order to disrupt the cells’ plasma 
membranes. Coverslips, with cells, were washed briefly with PBS and then mounted 
using a mounting medium, containing DAPI (4’, 6-diamidino-2-phenylindole) (5 
μg/ml). The slides were then inspected by DMR-X fluorescence microscopy (Leica, 
Germany). 
2.7 Cell cycle and apoptosis analysis by propidium-iodide 
staining using flow cytometry 
Briefly, 1x106 cells were grown in culture flasks for 24 hours, and then treated with 
freshly prepared cisplatin (see section 2.1 for stock preparation), at 37 oC in a 
humidified 5% CO2 atmosphere. After defined incubation times, floating cells from 
aspirated medium were collected by centrifugation at 1000 rpm for 5 minutes. 
Adherent cells were washed with PBS and harvested by trypsinization and the cell 
pellets were washed once with ice-cold PBS. Cell pellets were resuspended in 0.5 ml 
ice-cold PBS and 70% ethanol was added drop-wise to the cell suspension, up to a 
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final volume of 5 ml, while vortexing. Cells in 70% ethanol were then incubated at 4oC 
for 2 hours, with gentle agitation every half an hour to avoid clump formation. Then, 
cells were spun at 2500 rpm for 10 minutes, and cell pellets were washed twice with 
ice-cold PBS. 400 µl of propidium iodide (PI) (50 µg/ml) solution, containing 50 µl of 
DNAse-free RNAse A (100 µg/ml) were then added to the cells and the mixtures were 
incubated in the dark at room temperature (RT) for 30 minutes, before assay by flow 
cytometry.  Assessment of apoptotic cells by flow cytometric analysis was carried out 
on a Fluorescence-activated Cell Sorter (FACS) equipped with Cell Quest Pro 
Software (Becton Dickinson, UK). 
Apoptotic cells were distinguished from live cells on the basis of PI binding to low 
molecular weight DNA (fragmented DNA), compared to non-fragmented DNA.  
2.8 Apoptosis analysis by FITC-labelled Annexin V with flow 
cytometry  
After treatment of cells with drugs, floating cells from aspirated medium were collected 
by centrifugation and adherent cells were harvested by trypsinization. The cell pellets 
were washed 2 times in ice-cold PBS. Cells were then diluted with ice-cold binding 
buffer (0.01 M Hepes, pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2) at 1x106 cells/ml. To 100 
µl of cell suspension (105 cells), 5 µl of Fluorescein isothiocyanate (FITC)-labelled 
Annexin V (5 µg/ µl) and 10 µl of propidium-iodide (PI) (20 µg/µl) (BD Biosciences, 
UK) were added, and mixtures were incubated in the dark, for 15 minutes at RT. Then, 
300 µl of binding buffer was added, and samples were analysed using a BD Accuri 
flow cytometer, equipped with C6 software (BD Biosciences, UK).  
The cells were divided into 4 categories: 1) Live cells, i.e., those that excluded FITC 
Annexin V and PI; 2) Early apoptotic cells, i.e., those that bound only FITC Annexin 
V; 3) Late apoptotic or already dead cells, i.e., those cells that bound both FITC 
Annexin V and PI; 4) apoptotic or necrotic (death reason unknown), i.e., those cells 
that bound only PI (an example is shown in Figure 2.1).  
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Figure 2.1 Flow cytometric analysis of FITC Annexin V staining and PI.  
(A) cells were stain-free, (B) cells were incubated with only FITC Annexin V stain, (C) 
cells were incubated with FITC Annexin V and PI stain, (D) cells were incubated with 
only PI stain. Blue colour indicates live cells; green colour indicates early apoptotic; 
red colour indicates late apoptotic or already dead cells; black colour indicates 
necrotic or apoptotic cells.  
 
2.9 RNA isolation  
HepG2 parental and HepG2-cisplatin resistant cells were seeded at a density of 
≥1x106 cells per 25 cm2 culture flask and pre-incubated for 24 hours, to facilitate 
attachment to the bottom of flasks. Following subsequent cisplatin treatment, total 
RNA was isolated from cells, using the RNeasy kit (Quiagen, UK), according to the 
manufacturer’s instructions. Briefly, cells were lysed in RLT buffer and supernatant 
was obtained by centrifuging for 3 minutes at 13,000 rpm. The supernatant was mixed 
with 70% ethanol at a ratio of 1:1. Then, total mixture was transferred to an RNeasy 
spin column and centrifuged for 15 seconds at 8,000 rpm and the flow-through was 
discarded. Then, 700 µl RW1 buffer were added to the spin column and centrifuged 
for 15 seconds at 8,000 rpm and again the flow-through was discarded. Next, 500 µl 
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of RPE buffer were added to the spin column and centrifuged for 15 seconds at 8,000 
rpm and again the flow-through was discarded. Next, 500 µl RPE buffer were added 
to the spin column and centrifuged for 2 minutes at 10,000 rpm and the flow-through 
was discarded. After DNase treatment, total RNA was collected in 30 µl of RNase-
free H2O and was quantified by measurement of the absorbance at 260 nm (A260) 
using a Nanodrop spectrophotometer (Thermo Scientific, UK). The purity of RNA was 
confirmed using the A260/A280 method, where RNA has an A260/A280 ratio of 2.0. This 
method provides an estimate of the purity of RNA, with respect to other contaminants, 
such as protein, that typically absorb at 280 nm in the UV spectrum. For pure RNA, 
the value of A260/A280 ratio must be 1.9 - 2.1. The value of A260/A280 ratio was found to 
be 2.0 for the RNAs isolated in this study.      
2.10 Reverse transcription quantitative real time-PCR (qRT-PCR) 
The quantitative estimation of expression of TG2 mRNA and the “housekeeping” 
enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) controls were based 
on real-time monitoring of amplification and melting curves. Specific sequences of the 
primers for TG2 and other genes are summarized in Table 2.2. The reverse 
transcription was performed at 50 oC for 10 minutes, with 500 ng of total RNA, using 
specific reverse primers (Eurofins, UK) (Table 2.2) and iScript reverse transcriptase, 
from the one-step RT-PCR kit (Bio-Rad, UK), with some modifications to the 
manufacturer’s protocol. The reaction mixture contained: 12.5 µl 2x SYBR green PCR 
master mix; 1 µl (400 nM) forward primer; 1 µl (400 nM) reverse primer; 0.5 µl RT-
enzyme; total RNA and RNase-free H2O; in a total volume of 20 µl. Quantification 
based on real-time monitoring of amplification and melting curves was carried out 
using a Roche RT-PCR thermal cycler equipped with light cycler 4.1 software (Roche-
science, UK). The reaction mixtures were incubated in the following manner: cDNA 
synthesis during 1 cycle at 50 oC for 10 minutes; denaturation during 1 cycle at 95 oC 
for 5 minutes; 3 step amplification during 40 cycles, at 95 oC for 30 seconds, 60 oC 
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for 30 seconds, and 72 oC for 90 seconds; final extension during 1 cycle at 72 oC for 
10 minutes; melting curve generation during 1 cycle at 95 oC for 10 seconds, 44 oC 
for 1 minute, and 72 oC for 1 second; and a final cooling step during 1 cycle at 37 oC. 
All determinations were done in triplicate, together with one control reaction, in which 
RT enzyme was omitted. The latter was used to test for potential DNA contamination, 
and to act as a negative control with respect to primer dimer-oligomerization. Absolute 
numbers of mRNA molecules were normalised to GAPDH, to correct for differences 
in RNA concentration. Sequences of the primers used for subsequent amplification 
reactions were designed from available data on specific genes obtained from NCBI 
website. Amplified products were monitored by running samples on a 1.2% agarose 
gel and confirmed against available data. The relative quantification was calculated 
using the ΔΔCT (ΔΔCq) method.  
The formulae used to calculate relative quantification are given in Table 2.1:  
Table 2.1 Equations used to calculate relative expression of genes  
Samples 
e.g., 
1.Treated 
2. Not-
treated  
Cq 
value 
of 
GAP-
DH 
Cq 
value 
of        
TG2  
∆Cq                              
= (CqTG2-
CqGAPDH) 
∆Cq
Expression   
= 2-∆Cq 
Mean of 
∆Cq 
expression 
(average of 
replicates)   
∆∆Cq 
expression 
(normalise 
to control)  
Std Dev  
of ∆∆Cq 
expressi
-on  
 
Ratio expression (∆∆Cq) = Test expression/control expression            
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Table 2.2 Primers used for transcript quantification  
Transcript Name Sequence 
GAPDH (F) – CACTAGGCGCTCACTGTTCTC 
(R) – GACTCCACGACGTACTCAGC 
TG2 (F) – CTGGGCCACTTCATTTTGC 
(R) – ACTCCTGCCGCTCCTCTTC 
TG1  (F) –CTGCTCAATGTCTCAGGCCA 
(R) – CTTGGGCCTCTGTAACCCAG 
F = Forward primer, R = Reverse primer. 
2.11 Isolation of the nuclear fraction 
Cisplatin-treated HepG2 cells, and controls, were disrupted in homogenization buffer 
(250 mM sucrose, 10 mM Tris-HCl, pH 7.5, 2 mM EDTA,), containing 1% complete 
protease inhibitor cocktail (Aprotinin, Bestatin, Leupeptin, Pepstatin A) (SigmaAldrich, 
UK). The homogenates were centrifuged at 600 x g for 5 minutes at 4 oC, to yield a 
nuclear pellet and a non-nuclear supernatant. Nuclei were then resuspended in nuclei 
isolation buffer (20 mM Hepes, pH 7.9, 400 mM NaCl, 1.5 mM MgCl2, 0.5 mM 
dithiothreitol, 0.2 mM EDTA, 20% glycerol), again containing a cocktail of protease 
inhibitors. The mixtures were incubated at 4 oC for 1 hour with constant rotation, and 
then centrifuged at 17,000 x g for 20 minutes to obtain a supernatant fraction enriched 
with nuclear proteins. The non-nuclear supernatant was centrifuged at 17,000 x g for 
20 minutes at 4 oC. The supernatant that contained the remaining organelle proteins 
was collected and the total protein concentrations of samples were determined using 
the Bradford dye-binding assay (Bradford, 1976). 
2.12 Isolation of membrane proteins 
The membrane proteins were isolated using Mem-PER Plus Membrane protein 
extraction kit (Thermo Scientific, UK) according to the manufacturer’s instructions. 
Briefly, cells were collected by centrifugation and cell pellets were washed once with 
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wash solution (PBS).  Cell pellets were permeabilized in a state type buffer, containing 
a cocktail of protease inhibitors and incubated for 10 minutes at 4 oC, with constant 
mixing. Then, mixtures were centrifuged at 16,000 x g for 15 minutes at 4 oC and the 
supernatant containing cytosolic proteins was collected. The remaining pellets were 
re-suspended in solubilisation buffer (1-propanaminium, N,N-dimethyl-N-(3-
sulfopropyl)-3-[[(3α,5β,7α,12α)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-, inner 
salt) by slow pipetting up and down, until the pellets were broken. The cell 
suspensions were incubated for 30 minutes at 4 oC with constant mixing on a sample 
mixer. Then, samples were centrifuged at 16,000 x g for 15 minutes at 4o C and 
supernatants containing membrane proteins were collected and stored at -20 oC until 
required for assays.    
2.13 Whole Cell lysate preparation  
Cisplatin-treated, and untreated (control), HepG2 and HepG2/cr cells were washed 
twice with ice-cold PBS for 5 minutes each. Then, cells were directly lysed for 5 
minutes at 4 oC in cell lysis RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% 
NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) (Sigma Aldrich, UK) containing 
1% complete protease inhibitor cocktail. Cell suspensions were then vigorously 
vortexed and incubated on ice for 5 minutes, and then centrifuged at 17,000 x g for 
20 minutes at 4 oC. The protein-enriched supernatants were collected and stored at -
80 oC prior to analysis.      
2.14 Protein quantification by Bradford assay 
The total protein concentration of cell lysates were determined using the Bradford 
dye-binding assay (Bradford, 1976). Briefly, 3 ml of Bradford reagent (0.05 mg/ml 
Coomassie Brilliant Blue G-250, 10% phosphoric acid) were added to 50 µl of 
samples, before incubation of samples at RT for 45 minutes. After incubation, the 
optical density (absorbance) of colour formed was measured at 595 nm, using a 
spectrophotometer (Thermo Scientific, UK). The concentration of protein samples 
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was calculated by reference to a standard curve that had been constructed using 
known concentrations of Bovine Serum Albumin (BSA) as standards.    
2.15 Gel electrophoresis  
One dimensional (discontinuous) sodium dodesyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) was performed according to the method of Laemmli 
(1970). Samples were mixed with Laemmli 2x SDS Sample buffer (1:1) (125 mM Tris-
HCl, pH 6.8, 4% SDS, 20% glycerol, 2% β-mercaptoethanol, 0.02% bromophenol 
blue) and proteins were further denatured by heating at 90-95 oC for 5 minutes. 
Samples were then cooled and 20 µl aliquots were loaded and separated, using 10% 
Bis-Tris plus gels (Invitrogen, UK) under reducing conditions, with 1x MES SDS 
running buffer, in a bolt mini-gel electrophoresis tank (Life Technology, UK). The gels 
were run at 160 V and 80 mA, until the dye-front reached the bottom of the gels. Then, 
gels were either stained with Coomassie blue, or transferred to a nitrocellulose 
membrane for Western blot analysis.   
2.16 Western blotting  
SDS-PAGE gels (see section 2.15) were electrophoretically transferred to 
nitrocellulose membranes (Abcam, Cambridge, UK), using semi-dry transfer (Thermo 
Scientific, UK) for 1 hour, at 100 mA, 5 V. Transferred proteins were initially visualised 
by Ponceau S red (0.5 g in 100 mL 1% acetic acid) staining, before further processing. 
Blots were then blocked in a 5% non-fat dried milk powder, in Tris-buffered saline, 
with 0.1% Tween-20 (TBST) for 1 hour. The blots were gently washed, briefly, with 
TBST and incubated with anti-TG2 polyclonal antibody, at 1:3000 (v/v) dilution in 
TBST, for 3 hours at RT, or overnight at 4 oC, with rotation agitation. The blots were 
subsequently washed 3 times for 5 minutes with TBST, replacing the buffer each time. 
Then, HRP-conjugated secondary antibody was added at a 1:3000 (v/v) dilution and 
the blots were incubated for 1 hour at RT. The blots were then washed 3 times with 
TBST, for 5 minutes each time. The blots were subsequently developed, using an 
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enhanced luminol-based chemiluminescence substrate for the detection of 
horseradish peroxidase (HRP) (ECL-HRP Western blotting substrate) (Pierce, 
Thermo Scientific, UK). The antibodies were stripped off of the blot with stripping 
solution (0.5 M Tris-buffer, pH 6.7, 2% SDS, 0.7% β-mercaptoethanol) for re-
incubation with a loading control, using an antibody against β actin (Abcam, 
Cambridge, UK). The stripped blots were re-incubated with rabbit anti-β actin 
antibody at 1:3000 (v/v) dilution for 3 hours at RT, or overnight at 4 oC. Then, blots 
were washed as described above and incubated with secondary anti-rabbit antibody 
(1:3000 (v/v)) for 1 hour, then washed and developed as previously described. 
Table 2.3 Antibodies used for measurement of protein  
Antibody  Concentration  Company  
TG2 (rabbit) (SAB4200072)  1:3000 (v/v) Sigma Aldrich, UK 
TG2 (rabbit) (ab421) 1:3000 (v/v) Abcam, Cambridge, UK 
TG2 (mouse) (ab2368) 1:3000 (v/v) Abcam, Cambridge, UK 
β-actin (rabbit) (ab75186)  1:3000 (v/v) Abcam, Cambridge, UK 
Goat Anti-rabbit (ab6721) 1:4000 (v/v) Abcam, Cambridge, UK 
Goat anti-mouse (ab6789) 1:4000 (v/v) Sigma Aldrich, UK  
 
2.17 Development of immunoblots    
Blots were incubated with ECL substrate reagents (1:1 v/v ratio) for 1 minute. Then, 
excess reagents were drained and blots were covered with a clean plastic wrap. The 
protected membranes were placed in a film cassette with the protein side facing up. 
The protected membranes were then exposed to X-ray film in the dark, in the 
presence of red light, for 3 minutes. The film was subsequently developed in 
developing (5% hydroquinone in H2O) and fixing (25% ammonium thiosulphate in 
H2O) reagents and then washed with water and dried.    
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2.18 In vitro specific TG2 colorimetric microassay (TG2-CovTest)  
Cell lysates were prepared from HepG2 test samples and TG2 activity was measured 
using a commercially-available specific TG2 colorimetric microassay kit (Covalab, 
France), according to the manufacturer’s instructions. Briefly, the wells of a microtiter 
plate were pre-coated with amine substrate (spermine), and washed once with 1x 
PBS for 15 minutes at 37 oC. The buffer was removed and 50 µl of assay mixture 
(containing freshly-made dithiothreitol (DTT), biotin-pepT26/CaCl2) in double distilled 
water, were added. Then, 60 µl of lysate was added to each well. Samples were 
mixed by pipetting and incubated at 37 oC for 30 minutes. Wells were washed once 
with PBS, then washed once with 0.1 M NaOH, then washed twice with PBS. 
Streptavidin-labelled peroxidase solution (SAv-HRP) was added (100 µl) and the 
samples were incubated for 15 minutes at 37 oC. Wells were subsequently washed 
thrice with PBS and 100 µl aliquots of HRP-substrate (H2O2) were dispensed into 
each well. The mixtures were then incubated in the dark, for 5 minutes at RT. The 
reaction was developed by adding tetramethyl benzidine stock solution (100 µl) and 
the colour that formed was measured on the basis of its optical density at 450 nm, 
using a microplate reader.                 
2.19 CBZ-Gln-Gly assay of Transglutaminase activity  
Guinea pig liver transglutaminase activity was measured by Benzyloxycarbonyl-
Glutamine-Glycine (CBZ-Gln-Gly) assay, using the method of Folk and Cole (1966), 
with minor modifications. 1 ml samples contained a final concentration of 200 mM 
Tris-HCL (pH 7.0), 10 mM CBZ-Gln-Gly, 100 mM Hydroxylamine (NH2OH), 6 mM 
CaCl2, 1.6 mM DTT and 0.02 mg/ml guinea pig liver transglutaminase. Aliquots of 
freshly-prepared cisplatin were added to reaction mixtures over a concentration range 
of 0-128 µM in final volumes of 1 ml and incubated for 1 hour at 37 oC. The reactions 
were stopped by adding 0.3 ml of ferric chloride-trichloroacetic acid (FeCl3/TCA/HCl), 
and the precipitated products were centrifuged at 3000 rpm for 3 minutes. The optical 
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density of the supernatant was measured immediately, at 520 nm against a blank, in 
which TG2 was omitted. EDTA was added to negative samples.  
For determination of transglutaminase activity from cell lysates by CBZ-Gln-Gly 
assay, the protocol was the same as described above, except 100 µl of lysate was 
added to mixtures, instead of commercially-available guinea pig liver 
transglutaminase. 
2.20 siRNA inhibition of transglutaminase 2 (Tgase)  
For the siRNA inhibition study, the sequence of the siRNA oligomer (pre-designed 
and synthesized by Ambion, Life Technologies, UK) used to inhibit TG2 expression 
was as follows: sense:-GGCCCGUUUUCCACUAAGA, antisense:-
UCUUAGUGGAAAACGGGCC. Cells were transfected with oligomers, using 
Lipofectamine 2000 transfection reagent (Life Technologies, UK), according to the 
manufacturer’s instructions. Briefly, 1x105 cells were grown in 12-well plates or 4-well 
Lab Tek chamber slides prior to transfection. After 24 hours, cells were treated with 
a final volume of 4 µl lipofectamine and a final concentration of siRNA at 30 pmol in 
a total volume of 1 ml culture medium, and cells were re-incubated for 48 hours.  After 
the indicated time, cells were prepared for further analysis. Alternatively, cells were 
harvested, and cell lysates were prepared to measure protein expression of TG2 (see 
section 6.2.4).  
2.21 Immunocytochemistry   
HepG2 cells were grown on coverslips in 6-well culture plates at a density of 2x105 
cells/ml/well. Then, cells were treated or not treated with 8 µM cisplatin for 24 hours 
at 37 oC in a humidified 5% CO2 atmosphere. After incubation, cells were washed 
with ice-cold PBS and fixed in 4% formaldehyde (4% paraformaldehyde/0.2 M 
Sucrose/1x PBS, pH 7.5), and incubated for 15 minutes at RT. Then, cells were 
washed 2 times with PBS prior to incubation in blocking buffer (5% donkey 
serum/0.3% Triton X-100/1x PBS) for 1 hour at RT. The blocking buffer was then 
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replaced with anti-TG2 antibody solution (TG2 antibody at 1:200 in 1x PBS/1% 
BSA/0.3 Triton X-100) and incubated for 2 hours at RT, or overnight at 4 oC. The cells 
were then washed 3 times in PBS for 5 minutes each time. Then, cells were incubated 
in the dark, with Alexa Fluor 488-labelled Donkey anti-rabbit secondary antibody 
solution for 1 hour at RT. Finally, cells were washed 3 times in PBS for 5 minutes 
each, and cover slips were mounted with mounting medium containing DAPI. The 
slides were observed using LSM510 laser scanning confocal microscope (LSCM) 
(Zeiss, Heidelberg, Germany) at x400 magnification, with excitation wavelengths set 
at 488 nm and emission filter at 530 nm, or with a DMR-X fluorescence microscope, 
with detector filter set at 3 (Green filter) (Leica, Germany). 
2.22 Confocal microscopic detection of uptake of alexa fluor 
546/488 labelled cisplatin   
HepG2 and HepG2/cr cells were grown in 4-well glass Lab-Tek chamber slides 
(Nalge Nunc International, USA). Then, cells were incubated with Alexa Fluor 
546/488-labelled cisplatin (F-CDDP) (Molecular probes, Life Technologies, UK), at a 
final concentration of 200 U/ml (1 unit is defined as the reagent solution required to 
label 25 ng of DNA in vitro) (Yoshida, et al., 2011) for up to 2 hours. Then, cells were 
washed with ice-cold PBS and fixed with ice-cold 70% ethanol for 15 min at -20 oC. 
Subsequently, cells were washed with ice-cold PBS, mounted with fluorescence 
mounting medium (Sigma Aldrich, UK) and sealed with clear nail polish. The slides 
were then inspected using a LSM510 laser scanning microscope (Zeiss, Heidelberg, 
Germany), at x400 magnification, with wavelengths set at 543/530 nm for red 
fluorescence and 488/530 nm for green fluorescence.         
2.23 Alexa fluor 488-labelled cisplatin uptake assay by flow 
cytometry       
5 x 105 cells were grown in 6-well culture plates for 24 hours, then treated or not-
treated (controls), with Alexa fluor 488-labelled cisplatin, at a final concentration of 40 
U/ml for up to 2 hours. Then, cells were collected by trypsinisation, washed with ice-
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cold PBS and re-suspended in 300 µl ice-cold PBS. 10,000 cells were analysed 
immediately by BDAccuri C6 flow cytometry (BD Biosciences, UK) with the 
fluorescence intensity detector set at FL-1 (FITC; excitation max 488 nm and 
emission max 530 nm).     
2.24 Cellular uptake of dansylcadaverine by fluorescence 
microscopy  
A cellular uptake assay was performed by the method described by Hummerich and 
Schloss (2010), with some modifications. Briefly, 1x105 cells were grown on coverslips 
in 6-well culture plates. After 24 hours, cells were treated with 0-20 µM of 
dansylcadaverine, in the presence or absence of 2 mM cystamine, for up to 4 days. 
Following incubation, the medium was removed and coverslips with the cells were 
washed 2 times with PBS, for 5 minutes each. Then, cells were then fixed in 4% 
paraformaldehyde at 4 oC for 20 minutes. Coverslips were mounted in fluorescent 
mounting medium and inspected using a DMR-X fluorescence microscope (Leica, 
Germany) at x200 magnification, with the detector filter set at 3 (green filter). 
Photographic images were then recorded, using a microscope equipped with 
ProgRes Capture 2.7 software. 
2.25 Pepsin modification reaction  
The incorporation of dansylcadaverine (DNC) into pepsin was carried out in 0.5 ml of 
40 mM Tris-HCl, pH 8.0, with a final concentrations as follows: 2 mg/ml pepsin; 1 mM 
DNC; 10 mM DTT; in the presence or absence of 10 mM CaCl2. The commercial 
guinea pig transglutaminase (see section 2.19) was added in a ratio 1:10 w/w of 
enzyme to pepsin substrate. In negative controls, EDTA was added to give a final 
concentration of 30 mM. The reaction mixtures were incubated at 37 oC for up to 24 
hours. After predetermined time intervals (0, 1, 2, 5, 10, 24 hours), 100 µl of the 
reaction mixtures were removed for quantitative analysis (section 7.2.4) and the 
reaction was quenched by adding 30 mM of EDTA.   
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2.26 Gel filtration chromatography 
PD-10 Sephadex G-25 desalting columns (Sigma Aldrich, UK) were used for the 
separation of modified pepsin. The columns were initially equilibrated with 40 mM 
Tris-HCl buffer, pH 8.0, before 2 ml of sample mixtures in Tris-HCl buffer were applied 
to the column and the proteins were recovered by collecting 25 x 1 ml aliquots of 
eluent in single Eppendorf tubes. The absorbance of eluent was measured at a 
wavelength of 330 nm, at which dansylcadaverine gives maximum fluorescence (see 
figure 7.2).   
2.27 High Performance Liquid Chromatography (HPLC)    
DNC-labelled pepsin was purified, using semi-preparative HPLC (Perkin Elmer, UK) 
on a C18 reverse phase column (260 x 4.60 mm), attached with the ultraviolet eluent 
detector. For analysis, 20 µl of reaction mixtures were mixed with up to 1 ml 
acetonitrile and applied to a column with a linear gradient of buffer A (0.1% TFA in 
water) and buffer B (0.1% TFA in acetonitrile). The samples were eluted for 30 
minutes, at a flow rate equal to 1 ml/minute at ambient temperature. The eluted 
samples were detected and measured on the basis of UV absorption at 215 nm. 
2.28 Immunoprecipitation   
To isolate DNC-labelled proteins from cell lysates (see section 7.2.6), 200 µl of cell 
lysate were used. To each sample, 5 µl (5 µg) of anti-dansyl rabbit antibody (cat no. 
A-6398) (Invitrogen, UK) were added and samples were incubated on a rotating mixer 
shaker for 1 hour, or overnight, at 4 oC. Then, 30 µl of protein-A agarose slurry were 
added and incubated for another hour at 4 oC. The samples were then centrifuged at 
1000 x g for 3 minutes, to pellet immunocomplexes from the mixture. Pellets were 
washed 4 times with RIPA buffer, with centrifuging each time at 600 x g for 2 minutes. 
Following the final wash, the buffer was completely removed and 50 µl of 2x SDS-
Sample buffer was added to each pellet. Samples were then heated at 95 oC for 5 
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minutes, and centrifuged at 10,000 x g for 5 minutes, before supernatants containing 
immunoprecipitated DNC-labeled proteins were separated on 12% SDS-PAGE gels. 
2.29 Endoproteinase digestion  
The endoproteinase Glu-C (Sigma Aldrich, UK) was used to digest the DNC-labelled 
pepsin. The protein digestion was carried out in 100 mM Tris-HCl, pH 7.8, for 18 hours 
at 37 oC, at ratios of 1:20, 1:50, 1:100, and 1:200 (w/w) of enzyme to substrate. The 
peptide fragments were then separated by SDS-PAGE and gels were monitored 
under an ultraviolet fluorescent gel reader for detection of fluorescent bands, 
photographed and then stained with Coomassie blue dye.    
2.30 Statistical analysis  
All statistical analyses were performed using GraphPad Prism 6/7 software 
(GraphPad, USA). p values < 0.05 were considered to be statistically significant. The 
statistically significant differences in mRNA expression levels, enzyme activities, cell 
viability and cell death rates between the control groups and various treatment groups 
were assessed using the Student’s t test, and one way ANOVA with Dunnett’s 
multiple comparison test, wherever applicable. The p values are denoted symbolically 
as follows: 0.01-0.05 (*) = significant; 0.001-0.01 (**) = highly significant; 0.0001-
0.001 (***) = very highly significant; and < 0.0001 (****) = extremely significant.     
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CHAPTER 3:  
3. TRANSGLUTAMINASE 2 INVOLVEMENT IN CELLULAR 
UPTAKE OF DANSYLCADAVERINE  
3.1 Introduction   
The purpose of this chapter is to preliminarily determine whether TG2 has any role in 
cellular uptake of amine-based compounds using dansylcadaverine as an 
autofluorescent reporter molecule, in parental HepG2 cell lines. This work was 
conducted  as a pilot study before conducting further investigations on the uptake of 
the anti-cancer drug cisplatin both in parental and chemoresistant cells; the results of 
the latter work is discussed in subsequent chapters.   
Dansylcadaverine (DNC) is a substrate and an inhibitor of transglutaminase 2 
(Nunomura, et al., 2003). It is used in several studies to determine its inhibitory effects 
on TG2 enzymatic activity. In this chapter, the role of TG2 in cellular uptake of DNC 
in HepG2 and CAKI2 cell lines was investigated. Findings from this chapter suggest 
a role for TG2 in cellular uptake of DNC and lead on to further studies investigating 
the role of TG2 in cellular uptake of the anti-cancer drug cisplatin in chemoresistant 
cells (chapter 4-6).  
3.2 Results and discussion  
3.2.1 Determination of dansylcadaverine toxicity to HepG2 cells  
DNC was chosen for cellular uptake studies as it is a relatively non-toxic molecule 
(Ray and Samantha, 1996). For determination of cytotoxicity of dansylcadaverine, 
cells were incubated with 0-300 µM DNC for 48 hours and toxicity was measured by 
CCK-8 assay. Significantly, no toxic effect was seen with DNC (figure 3.1). Although 
there is no cytotoxicity of DNC measured over the 0-300 µM range, a relatively low 
concentration of 10 µM was chosen for uptake studies as below 100 µM DNC acts as 
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a substrate, whereas over 100 µM DNC acts as an inhibitor of TG2 and it was felt that 
higher concentrations of DNC treatment might therefore add an extra level of 
complexity to the interpretation of results.   
 
Figure 3.1 Dansylcadaverine cytotoxicity to HepG2 cells. 
HepG2 cells were incubated over a range of 0-300 µM DNC for 48 hours and 
toxicity was measured using the CCK-8 viability assay. Results are ±SD of 
triplicate experiments.      
 
The combined cytotoxicity of DNC and the TG2 inhibitor cystamine was measured by 
flow cytometric analysis, using cells that had been incubated for 4 days, either with, 
or without 10 µM, 20 µM, 50 µM DNC, both in the presence or absence of 2 mM 
cystamine.  
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Figure 3.2 Apoptosis and cytotoxicity determination after DNC and 
cystamine treatment.  
HepG2 cells were treated with 0-50 µM DNC either in the presence or absence 
of 2 mM cystamine (cys). After 4 days, cell viability was observed by FITC-
labelled anexin-V by flow cytometry. 
 
Cells survived in the presence of cystamine for up to 4 days at non-lethal doses of 
DNC (figure 3.2). 
3.2.2 Cystamine treatment increases internalisation of 
dansylcadaverine  
Whereas some drugs can cross the plasma membrane by passive diffusion, it is now 
established that the cellular uptake of many molecules occurs through specific 
mechanisms of endocytosis (carrier-mediated transpost) (Mellman and Yarden, 
2013). In order to investigate whether transglutaminase (TGase) is involved in such 
mechanisms of cellular uptake, HepG2 cells were incubated with 5 µM and 10 µM 
DNC in the presence or absence of TG2 inhibitor 2 mM cystamine, and cellular uptake 
was examined by fluorescent microscopy. Cystamine inhibits TG2, most likely by 
forming a mixed disulphide bond with cysteine residue(s) of the catalytic core. Also, 
it has been suggested that, in addition to inhibiting TG2, cystamine may also interfere 
with and possibly inhibit other thiol-dependent enzymes. Although cystamine is a non-
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specific compound, it is a more efficient modulator of TG2 activity than many other 
enzymes.  
 
Figure 3.3 Cellular uptake of dansylcadaverine in HepG2 cells.  
HepG2 cells were grown on coverslips and incubated with DNC either in the presence 
or absence of 2 mM cystamine for 4 days. After 4 days, cells were washed, fixed and 
mounted with fluorescent mounting medium and observed using a DMR-X 
fluorescence microscope at x200 magnification. Scale bar = 25 µm. a) 5 µM DNC, b) 
5 µM DNC + cystamine, c) 10 µM DNC, d) 10 µM DNC + cystamine. All images were 
taken using Progress-Capture software with colapse time at 3215 Sec and 0 gains. 
 
 
The results show that after 4 days of incubation, there was no significant uptake of 
DNC in control (untreated cells) (figures 3.3A and C). However, treatment of cells with 
TG2 inhibitor cystamine resulted in a large increase in DNC uptake by cells (figures 
3.3B and D).  
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Figure 3.4 Transaminase activity is decreased during cellular uptake of 
dansylcadaverine.  
HepG2 cells were treated with different concentrations of dansylcadaverine (DNC) in 
the presence or absence of 2 mM cystamine for 4 days. Tranglutaminase activity was 
measured from cell lysates using CBZ-Gln-Gly assay. The activity is represented as 
optical density measured at 520 nm. The statistical differences between treated and 
untreated groups were calculated by Student’s paired t-test 
 
The total transglutaminase activity was significantly reduced in cystamine-treated 
cells (figure 3.4), indicating that transglutaminase may be involved in the 
internalisation of DNC by cells.   
3.2.3 TG2 gene silencing increased uptake of dansylcadaverine.  
To confirm that the presence of TGase in the cell was obstructing the uptake of DNC, 
the expression of the TG2 gene was inhibited by transfecting siRNA molecules into 
the cells. The HepG2 cells were treated or not-treated with 30 pmol siRNA specific to 
the TG2 gene in the presence of 10 µM DNC for 4 days, with the help of transfecting 
agent lipofectamine2000.  
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Figure 3.5 TG2 gene silencing increased uptake of DNC. 
HepG2 cells were treated or not-treated with siRNA in the presence of 10 µM DNC 
and incubated for 4 days. After incubation, cells were washed with PBS, fixed with 
4% paraformaldehyde, mounted with fluorescence mounting medium and observed 
using a DMR-X fluorescence microscope at x100 magnification; Scale bar = 50 µm. 
(A) 10 µM DNC + lipofectamine, and (B) 10 µM DNC + lipofectamine + siRNA. 
 
The results indicate that the inhibition of TG2 caused accumulation of DNC into 
treated cells (figure 3.5B), whereas control (siRNA untreated) cells showed 
considerably less DNC uptake (figure 3.5A).  
3.2.4 Cellular uptake of DNC is increased in CAKI2 cell line  
The same effects on the cellular uptake of DNC were observed in CAKI2 cells after 
inhibition of TG2 i.e., after 4 days of incubation, there was no significant uptake of 
DNC in control (cystamine untreated) cells (figures 3.6A and C), whereas there was 
visible uptake of DNC into cystamine treated cells (figures 3.6B and D).  
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Figure 3.6 Dansylcadaverine uptake in CAKI2 cells after 4 days.  
CAKI2 cells were incubated with 5 µM and 10 µM DNC in presence or absence of 2 
mM cystamine for 4 days. Then cells were fixed, mounted in fluorescence mounting 
medium and inspected using DMR-X fluorescent microscopy at x200 magnification. 
Scale bar = 25 µm. (A) 5 µM DNC, (B) 5 µM DNC + 2 mM cystamine, (C) 10 µM DNC, 
and (D) 10 µM + 2 mM cystamine. 
 
Results thus indicated that TG2 may have been involved in DNC transport both in 
liver (HepG2) and kidney (CAKI2) cells. However, the exact relationship between TG2 
and transport of drugs across the cell membrane needs to be investigated. 
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3.3 Conclusion   
Collectively, these results indicate that the presence of TG2 in the cells may be 
responsible for reducing the cellular uptake of dansylcadaverine both in HepG2 and 
CAKI2 cell lines, and therefore may possibly be involved in the modulation of uptake 
of other compounds/drugs in these and other cell types.    
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CHAPTER 4: 
4. TRANSGLUTAMINASE 2 RESPONSE TO CISPLATIN 
TOXIFICATION OF HEPATOCARCINOMA CELLS 
4.1 Introduction  
This chapter provides information as to how TG2 responds to cisplatin treatment 
before the development of resistance of HepG2 cells to cisplatin; this information is 
necessary in determining the role of TG2 in the mechanism(s) of the development of 
drug resistance.    
Over the past two decades, TG2 involvement has been shown in several apoptotic 
as well as anti-apoptotic pathways, both in vivo and in vitro, though the precise 
mechanism of its action remains currently poorly understood (Fésüs and Szondy, 
2005; Cao, et al., 2008; Cho, et al., 2010; Cho, et al., 2012; Yoo, et al., 2012; Rossin, 
et al., 2012; Hsieh, et al., 2013). Indeed, whether TG2 facilitates or ameliorates 
apoptosis appears to be dependent on the types of stressors and cells, and the 
specific isoform of TG2 that is expressed (Antonyak, et al., 2006). Some studies have 
shown that transamidation activity is required for cell death, whereas other studies 
have suggested a role for transamidation activity in cell survival (Gundemir and 
Johnson, 2009b; Gundemir, et al., 2013). TG2 has been found to be expressed in 
several cellular compartments, including the nucleus, cytoplasm, mitochondria, and 
extracellular matrix (ECM), depending on the cell’s physiological and pathological 
conditions (Nurminskaya and Belkin, 2012; Eckert, et al., 2014; Piacentini, et al., 
2014).   
Some reports have also shown that TG2 overexpression and activation have been 
linked to induction of the initiation of apoptosis, after treatment with chemotherapeutic 
drugs (Fok and Mehta, 2007; Robitaille, et al., 2008; Park, Choi and Ha, 2010; Yoo, 
et al., 2012; Hsieh, et al., 2013). Other studies show that down-regulation of TG2 
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appears to sensitize cancer cells to apoptosis (Nadalutti, et al., 2011). Consequently, 
different observations related to TG2 expression might reflect altered roles for TG2 in 
different cell lines and may be dependent on the specific conditions used for 
investigation (Nadalutti, et al., 2011).  
Cisplatin is one of the most effective drugs in the treatment of several types of cancer. 
However, owing to the limitation of its cytotoxic side effects on healthy cells and 
consequent damage to vital organs, it cannot be used at high doses i.e., >100 mg/m2. 
This problem is increased, as cancer cells that are able to evade the cytotoxic effects 
of low dose cisplatin treatment become resistant to normal concentrations used for 
treatment (Shen, et al., 2012). Mechanistically, cisplatin appears to cause cytotoxicity 
in cancer cells via nucleophilic attack, inducing cross-linking of DNA, defective repair 
of DNA and through depletion in the cellular levels of glutathione and metalothionein  
that are normally required to inactivate cisplatin (Gonzalez, et al., 2001; Dasari and 
Tchounwou, 2014; Galluzzi, et al., 2014). Cisplatin also can bind to RNA and other 
enzymes (Gonzalez, et al., 2001); the ways that cisplatin exerts its effects are still not 
fully understood.  
TG2 has been found to be induced and activated upon treatment with various anti-
apoptotic agents in several models of apoptosis (Uray, Davies and Fesus, 2001). 
However, the mechanism controlling TG2 expression after drug treatment is 
unknown. In order to investigate the molecular mechanism of cisplatin in relation to 
apoptosis, and how TG2 contributes to apoptotic pathways, the effects of the cytotoxic 
chemotherapeutic drug cisplatin on TG2 expression profile of mRNA, protein and 
enzymatic activity in the presence and absence of retinoic acid, and TG2 inhibitor 
cystamine were investigated in the human liver cancer HepG2 cell line.   
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4.2 Results 
4.2.1 Determination of cisplatin inhibitory concentration (IC50)   
HepG2 cells were incubated with increasing concentrations of cisplatin (0-20 µM) for 
24 and 48 hours and cytotoxicity was measured by CCK-8 assay (see section 2.4). It 
was confirmed from the cell survival curve that cisplatin had a concentration-
dependent cytotoxic effect on HepG2 cells, and as incubation time was increased, 
more cells died by apoptosis. The IC50 values for 24 and 48 hours were 8 µM and 4 
µM, respectively (figure 4.1).  
 
 
Figure 4.1 Cytotoxicity of cisplatin to HepG2 cells.  
HepG2 cells were incubated with increasing concentrations of cisplatin over 
24 and 48 hours and cell viability was measured by CCK-8 assay. The IC50 
value from 24 hours’ incubation was statistically different from the IC50 of 48 
hours incubation. The ***p value = 0.0007 by two-tailed Student’s paired t-
test. Results are means ± SD of triplicate assays from five independent 
experiments. 
 
The IC50 values were confirmed by flow cytometric analysis of cell death using 
Annexin V assay (see figure 5.1 in chapter 5). The IC50 values obtained were different 
from the IC50 previously reported from various studies (Table 4.1). However, the cells’ 
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response to drug may be depend on the cells’ condition/passage number and 
methods used for the cytotoxicity assay.   
Table 4.1 IC50 values in HepG2 cell line obtained from different studies after 24 
hours’ incubation  
IC50 Methods  References  
8.3 µM                    MMT (Luo, Jin and Huang, 2012)     
33.3 µM                    MMT (Uray, Davies and Fesus, 2001)      
106.3 µM                      MMT (Qin and Ng, 2002) 
4 µM                         CCK-8 (Odii and Coussons, 2012)    
40 µM MMT  (Zhang, Niu and Zhou, 2010)      
 
4.2.2 Apoptosis and cell cycle determination after cisplatin treatment  
Following treatment of HepG2 cells with 8 µM cisplatin for 12 and 24 hours, induction 
of apoptosis was measured by harvesting cells and estimating the DNA-based 
propidium iodide levels. Although cisplatin is known to induce apoptosis as early as 
at 12 hours after treatment at high dose (50 µM) (Qin and Ng, 2002), results indicated 
that there were no signs of apoptosis at this point with 8 µM cisplatin (figures 4.2A 
and B). However, following incubation for 24 hours, cisplatin-treated cells generated 
an extra apoptotic peak before G0/G1 phase (indicated by the arrow in figure 4.2D), 
that was not apparent in untreated control cells ( figure 4.2C). When incubation time 
was increased to 48 hours, more cells became apoptotic (see figure I.3 in appendix 
I). The morphological nuclear changes and the formation of apoptotic cell bodies were 
confirmed by DAPI staining observed by fluorescent microscopy. While untreated 
cells had a regular nuclear shape and showed no DNA condensation and/or 
fragmentation (figure 4.2G), cisplatin-treated cells revealed larger and irregularly-
shaped nuclei, and showed signs of both DNA condensation and fragmentation 
(figure 4.2H). Further evidence that apoptosis had been induced by cisplatin 
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treatment was provided by FITC-labelled Annexin-V flow cytometric analysis (figures 
4.2E and F), that indicated the presence of phosphatidylserine on the surface of 
cisplatin-treated cells, following incubation for 24 hours.   
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Figure 4.2 Apoptosis induction following cisplatin treatment. 
Apoptosis in HepG2 cells was measured by flow cytometry using propidium iodide-
staining. Cells were treated with 8 µM cisplatin for 12 hours (A - control; B - cisplatin 
treated), or 24 hours (C - control; D - cisplatin treated). FITC-labelled Annexin V flow 
cytometric analysis of apoptosis was conducted after incubation for 24 hours (E - 
control; F - cisplatin treated). In figures E and F, Q1 indicates dead cells; Q2 - live; 
Q3 - late apoptotic; Q4 - early apoptotic. DNA condensation and fragmentation 
analysis by fluorescent microscopy with DAPI staining is shown after treatment for 24 
hours with or without 8 µM cisplatin (G - control; H - cisplatin treated), where the red 
arrows indicate cells undergoing apoptosis (x200 magnification); Scale bar = 25 µm. 
Results are representatives of triplicate experiments. Untreated cells were used as 
controls.  
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4.2.3 TG2 transcriptional expression after treatment with cisplatin  
To investigate the molecular mechanism of cisplatin in relation to apoptosis, and the 
role of TG2 in apoptotic pathways, the effect of cisplatin treatment on TG2 gene 
expression in HepG2 cells was studied. Cells were treated with 0, 4 and 8 µM cisplatin 
for 6, 12 and 24 hours, respectively.  
  
Figure 4.3 Effects of cisplatin on TG2 at the transcriptional level.  
(A) TG2 mRNA expression measured by quantitative RT-PCR. HepG2 cells 
were incubated with cisplatin for 24 hours. Results are means ±SD of 
triplicates of three independent experiments. The *p = 0.01 by one way 
ANOVA with Dunett’s multiple comparison test relative to the control. (B) PCR 
products analysed by 1.2% agarose gel electrophoresis (lanes: 1 – control; 2 
- 4 µM cisplatin; 3 - 8 µM cisplatin). PCR products were confirmed against 
available online data from which primers were designed (NCBI Nucleotide 
database).  
 
Gene expression at the mRNA level was measured by RT-PCR using specific primers 
designed for TG2 mRNA. HepG2 cells treated for 6 and 12 hours expressed the TG2 
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gene at a low level; no significant difference was observed when controls compared 
to treatments groups (not shown). This trend continued and after 24 hours, TG2 
mRNA expression decreased in cisplatin-treated cells compared to control groups 
(figure 4.3A). This result was independently confirmed by isolating PCR products by 
agarose gel electrophoresis (figure 4.3B). The housekeeping gene GAPDH was used 
for normalisation of any general changes due to cisplatin.  
4.2.4 TG2 protein translational expression after cisplatin treatment  
To determine the relationship between cisplatin and TG2 protein expression during 
apoptosis, cells were treated with 0-16 µM cisplatin for 12 and 24 hours. After 
incubation of cells for 12 hours, no change was detected in TG2 protein expression 
(figure 4.4A). However, after incubation for 24 hours, like its mRNA, TG2 protein 
expression was reduced in cisplatin-treated cells compared to untreated cells (figure 
4.4B), and apoptosis was induced (figure 4.2D). This suggests that cisplatin may 
induce apoptosis initiation by inhibiting mRNA and thus TG2 protein production. To 
determine the subcellular distribution of TG2 during cisplatin-induced apoptosis, 
cytoplasmic and nuclear fractions were isolated. TG2 was only seen in samples from 
cytoplasmic extracts and none was detected in the nucleus (figure 4.4C).      
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Figure 4.4 Effects of cisplatin on TG2 protein expression.  
HepG2 cells were treated with cisplatin (lane 1 - control; lane 2 - 4 µM; lane 3 
- 8 µM; lane 4 - 12 µM; lane 5 - 16 µM cisplatin) and expression was measured 
by Western blot analysis following treatment for (A) 12 hours, and (B) 24 
hours. (C) The nuclear and cytoplasmic extracts were fractionated following 
incubation for 24 hours, either with or without cisplatin. The sample labelling 
of figure C, is same as of figure (B) for the lanes 1-5. The anti-TG2 antibody 
used was raised in the rabbit. Results are typical representatives of triplicate 
experiments. 
 
4.2.5 Effect of cisplatin treatment on TG2 transamidation activity  
To investigate whether transamidation activity has any role during cisplatin-induced 
apoptosis, cell lysates were prepared following 12 and 24 hours’ of treatment with 0-
16 µM cisplatin. TG2 activity was measured in cisplatin-treated cell lysates, using a 
specific in vitro TG2 CovTest kit. The TG2 present in 60 µl of cell lysate was added 
to the reaction mixture and the remaining assay was performed according to 
manufacturer’s instructions. The optical density was measured at 450 nm.  
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Figure 4.5 Effects of cisplatin on TG2 transamination activity. 
Transglutaminase 2 activity was measured with the specific TG2-CovTest kit. 
Cells were treated with 0-16 µM cisplatin for (A) 12 and (B) 24 hours. Samples 
were derived from 60 µl of cell lysate. Results are means ±SD of triplicates of 
three independent experiments. The p = 0.05 was not statistically significant 
between test and control groups calculated by one way ANOVA with Dunett’s 
multiple comparison test.     
 
The pattern of TG2 activity broadly reflected that of TG2 protein expression. After 
incubation for 12 hours, TG2 transamination activity was little changed in cisplatin-
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treated cells compared to untreated cells (figure 4.5A). After 24 hours, as cisplatin 
concentration was increased, TG2 transamidation activity decreased in a 
concentration-dependent manner, by approximately 50% compared to untreated cells 
(figure 4.5B), (although the p value was not statistically significant when compared 
between groups. p = 0.5).  
Although the reduction in TG2 activity appears to reflect the reduction in protein 
expression and the level of mRNA – there is a possibility that cisplatin could inhibit 
TG2 activity by competing with intracellular TG2 substrate proteins, possibly via 
amine groups present in cisplatin. Thus, this effect was tested directly in vitro on 
commercially-available guinea pig liver transglutaminase 2 activity (see section 
4.2.10). 
4.2.6 Inhibition of TG2 activity by cystamine induced apoptosis from 12 
hours post-treatment 
Cisplatin is known to induce apoptosis as early as at 12 hours post-treatment in the 
HepG2 cell line at a higher dose (50 µM) (Qin and Ng, 2002). To determine whether 
TG2 transamidating activity was involved in apoptosis induction, HepG2 cells were 
pre-incubated with or without a non-cytotoxic dose of 1 mM cystamine for 48 hours. 
Cells were subsequently left without further treatment (control), or, were treated with 
8 µM cisplatin and incubated for a further 6 to 12 hours.  
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Figure 4.6 TG2 inhibition by cystamine induced apoptosis  
HepG2 cells were pre-incubated with or without a non-lethal dose of 1 mM 
cystamine for 48 hours. Then, cystamine-treated cells were left untreated or 
were treated with 8 µM cisplatin for 6 and 12 hours, and cells were analysed 
by flow cytometry using propidium iodide staining.       
 
Results indicate that initiation of apoptosis was induced as early as 12 hours post 
cisplatin-treatment in cystamine pre-treated cells (figure 4.6), whereas apoptosis was 
not induced in cisplatin-treated cells that had not been exposed to cystamine (see 
figure 4.2B).         
4.2.7 Retinoic acid increased TG2 expression   
Retinoic acid (RA) is known to be one of the activators of TG2 at the transcriptional 
level, operating via nuclear receptors, in several cell types. It plays a role in cell 
differentiation. It has been used as a maintenance therapy for some cancers prior to 
testing with anti-cancer drugs. RA-activated TG2 has thus been implicated in cell 
survival (Singh, Li and Cerione, 1998; Ou, et al., 2000; Antonyak, et al., 2001; Singh, 
et al., 2001; Kweon, et al., 2004).  In order to determine the level of up-regulation of 
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TG2 by RA, HepG2 cells were treated with 10 µM RA continuously for 72 hours. As 
a preliminary step, the cytotoxicity of RA was measured by flow cytometric analysis. 
The results show that retinoic acid has no toxic effects on HepG2 cells at the 
concentration at which cells were treated; in fact RA-treated cells showed a higher 
percentage of live cells compared to non-treated cells (figure 4.7B). The morphology 
of cells was observed by inverted phase contrast microscopy, and showed that the 
RA-treated cells’ shape changed, to resemble neuron-like structures (figure 4.7A). 
Both TG2 protein expression and enzymatic activity were increased in RA-treated 
cells compared to non-treated cells (figure 4.7C and D). TG2 was maximally 
expressed after 72 hours’ of incubation.          
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Figure 4.7 Effect of retinoic acid treatment  
HepG2 cells (2x105 cells/25 cm2 flask) were treated with 10 µM retinoic acid (RA) 
continuously for 72 hours. After incubation, (A) changes in cell morphology were 
observed by inverted phase contrast microscopy, x200 magnification; images were 
taken using iphone 5 camera. Scale bar = 6.5 µm. (B) toxicity of 0-20 µM retinoic acid 
to cells was measured by flow cytometry, (C) TG2 protein expression was measured 
by Western blotting and densitometry analysis, (D) Transaminase activity was 
measured by CBZ-Gln-Gly assay. Plates A, C and D show effects of 10 µM retinoic 
acid; TG2 was maximally expressed after 72 hours’ of incubation.    
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4.2.8 Protective role of RA treatment on cell death induced by cisplatin  
Retinoic acid is a receptor activator for several enzymes at the transcriptional level 
including TG2, during the cell cycle and in cell differentiation. In order to test the 
hypothesis that overexpression of TG2 inhibits cisplatin-induced cell death, HepG2 
cells were treated with 10 µM RA for 72 hours. The cells were then treated with 8 µM 
cisplatin for 48 hours and cell death was analysed by FITC-labelled Annexin V flow 
cytometric analysis, using untreated cells as controls. 
  
Figure 4.8 Effect of retinoic acid pre-treatment of HepG2 cells on 
cisplatin toxicity   
HepG2 cells (2 x 105 cells) were treated with 10 µM RA and incubated for 72 
hours. After incubation, cells were either not treated or were treated with 8 µM 
cisplatin for a further 48 hours. Then samples were analysed by FITC-labelled 
Annexin V flow cytometry. Untreated cells were used as controls. The results 
are means ±SD of triplicate experiments.   
 
The results shown in figure 4.8, indicate that the RA-treated cells had a greater 
proportion of viable cells (50%), compared to RA-non-treated cells (20% viable cells) 
in cisplatin treated groups.      
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4.2.9 Inhibition of TG2 decreased cell viability 
To determine whether TG2 is involved in cellular protection against cisplatin 
treatment, HepG2 cells were incubated with 10 µM RA for 72 hours. The RA-treated 
cells were pre-incubated with 1 mM cystamine for 48 hours and then treated (or left 
untreated in the case of controls) with 8 µM cisplatin for 48 hours; cell viability was 
measured by flow cytometry.   
 
  
 
Figure 4.9 Effects of pre-treatment of HepG2 cells with retinoic acid on 
cystamine potentiation of cisplatin toxicity.  
HepG2 cells (2 x105 cells) were pre-treated with 10 µM retinoic acid for 72 
hours. Then, cells were treated or were not treated with 1 mM cystamine (cys) 
for another 48 hours. After incubation with cystamine, cells were treated or not 
treated with 8 µM cisplatin for a further 48 hours, and cell death was analysed 
by FITC-labelled Annexin V by flow cytometry. Results are means ±SD of 
triplicate experiments.  
 
 
Results indicate that treatment with cystamine appeared to increase cell death (figure 
4.9).  These observations indicate that higher levels of TG2 activity were correlated 
with reduced cell death; an example of TG2 activity inhibition with cystamine alone is 
shown in figures 3.4 and 6.4A, in chapters 3 and 6, respectively.    
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4.2.10 Direct effects of cisplatin on commercially-available exogenous 
guinea pig liver Transglutaminase  
To confirm whether cisplatin can cause direct inhibition of TG2, the effect of cisplatin 
was tested on purified guinea pig liver transglutaminase enzyme, using the CBZ-Gln-
Gly activity assay (see section 2.19). The inclusion of cisplatin into CBZ-Gln-Gly 
assay mixtures containing purified guinea pig liver transglutaminase caused a direct 
concentration-dependent inhibition of CBZ-Gln-Gly transamination over the whole 0-
128 µM range assayed.  
 
Figure 4.10 Effect of cisplatin on guinea pig liver transglutaminase 
activity in vitro. 
Transglutaminase activity was measured by CBZ-Gln-Gly assay. Cisplatin 
was used over the range of 0-128 µM on a 0.02 mg/ml guinea pig liver 
transglutaminase solution for 1 hour. Results are means ±SD of duplicates of 
three independent experiments. All cisplatin-treated groups were compared 
with control groups using one way ANOVA with Dunnett’s multiple comparison 
test.  
 
The results obtained were consistent with, though less pronounced than, the 
decrease in cellular transamination activity measured, following treatment of HepG2 
cells with cisplatin, requiring 128 µM of cisplatin to reduce the activity by 50% in vitro 
(figure 4.10). 
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Figure 4.11 Time-dependent effect of cisplatin on Tgase activity  
Transglutaminase activity was measured by CBZ-Gln-Gly assay. Cisplatin 
was used over the range of 0-128 µM on a 0.01 mg/ml guinea pig liver 
transglutaminase solution for 0-24 hours. Results are means ±SD of 
duplicates of three independent experiments.  
 
Interestingly, the incubation of cisplatin together with TG2 over 6 hours resulted in a 
loss in apparent cisplatin activity; this may reflect deactivation of cisplatin by aqueous 
hydrolysis or TG2 (figure 4.11). In addition nucleophiles like amide-NH2 of Gln-
tripeptide in the TG2 activity assay, -SH and amino groups of proteins, and the 
imidazole of histidine can reduce the concentration of active cisplatin in test assays, 
especially over long incubation times. This observation may explain why 100 µM 
cisplatin was required to induce its cytotoxic effect after 24 hours, as observed in 
other studies (Table 4.1).   
4.3 Discussion  
TG2 is a multifunctional protein that has been implicated in several cellular processes, 
including apoptosis and cell survival (Fésüs and Szondy, 2005; Nurminskaya and 
Belkin, 2012). Increased TG2 expression has been linked with cell survival in several 
cancer cells (Cho, et al., 2010; 2012). Over the past five decades, several cases of 
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resistance to cisplatin-induced apoptosis have evolved, and in some cases TG2 has 
been identified as one of the regulators of such processes (Jang, et al., 2010).  
In this study, the results show that in the human hepatocarcinoma HepG2 cell line, 
cisplatin modulates TG2 by down-regulating its expression (figures 4.3 and 4.4) and 
that it is also capable of directly inhibiting TG2 ’s enzymatic, transaminating activity 
during the induction of apoptosis (figure 4.5). Also, some studies have shown that 
upon initiation of the death response, TG2 translocates to the nucleus (Gundemir and 
Johnson, 2009; Kojima, Kuo and Tatsukawa, 2012). This study observed no such 
translocation (figure 4.4C); this effect may be dependent on differences in cellular 
conditions.  Interestingly, Fesus & Zondey (2005) have suggested that loss of TG2 
activity in mice could cause compensatory induction of other transglutaminases (TG1, 
3, 5 and 7); this appears to be the case during cisplatin treatment of hepatocarcinoma, 
as this study observed the activation of TG1 at mRNA level following the treatment of 
HepG2 cells with cisplatin (see figure I.1 in appendix I). This effect of cisplatin on TG1 
expression was measured along with TG2 mRNA expression.  
TG2 upregulatory studies using retinoic acid confirmed that TG2 may be involved in 
the delay/inhibition of apoptosis induced by cisplatin, and that its inhibition by 
cystamine was required to reverse this effect (figures 4.6 and 4.9). This effect could 
be explained if the presence of TG2 in liver works as a detoxifier of cisplatin; this 
notion is supported by the observation that incubation of cisplatin with TG2 for 12 
hours reduced the inhibitory activity of cisplatin on TG2 activity (figure 4.10. and 4.11), 
possibly by binding at a catalytic site.  
Taken together, the findings indicate that cisplatin may required, first to inhibit TG2 
prior to induction of apoptosis; which explains how the high abundance of TG2 in liver 
may be involved in prevention of apoptosis induction by chemotherapy drugs and 
could contribute significantly to the development of cisplatin-resistant in HCC 
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patients. On the basis of this hypothesis the TG2 expression profile is investigated in 
cisplatin-treated drug-resistant HepG2 cells in next chapter.  
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CHAPTER 5: 
5. EXPRESSION OF TRANSGLUTAMINASE 2 IN CISPLATIN-
RESISTANT HEPATOCARCINOMA HEPG2 CELL LINE 
5.1 Introduction  
As observed in chapter 4, increased TG2 expression reduces the cisplatin 
cytotoxicity. Thus, this chapter is focused on developing a drug resistance HepG2 cell 
line and comparing the TG2 expression profile to parental cells before conducting the 
costly cellular uptake studies using fluorescent-labelled cisplatin in the following 
chapter.    
Drug resistance is becoming the major obstruction to successful cisplatin-based 
chemotherapy. Cells that become resistant to cisplatin involve both intrinsic and 
acquired changes at the genetic and/or epigenetic level, initiating cellular self-defence 
mechanisms by activating or silencing several cellular proteins and enzymes. These 
changes may occur during single-dose or multiple-dose treatment with anti-cancer 
drugs (Shen, et al., 2012; Holohan, et al., 2013).  
Cisplatin is one of the most effective and extensively-used drugs to treat several 
cancers, but because of its high cytotoxicity to non-cancerous cells its use had been 
limited, and later, cancer cells have shown more resistance to cisplatin (Gumulec, et 
al., 2014; Galluzzi, et al., 2014). In recent years, the use of cisplatin in 
hepatocarcinoma treatment has been improved and increased, but chemoresistance 
remains a major problem. Different drug-resistant cell lines to cisplatin have been 
developed to elucidate the mechanisms and important key proteins and enzymes 
underlying this process. Thus, studies are needed to identify such proteins or 
enzymes that contribute to the drug resistance mechanisms, in order to target them 
to overcome drug resistance.                     
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Recent studies have shown that alterations in TG2 expression occur during the  
development of drug resistance in several cancers, including overexpression of TG2 
in drug-resistant breast, ovarian, glioblastoma, head and neck, colon, melanoma, 
lung, pancreas and renal cancer cells (Mehta, et al., 2004; Verma, et al., 2006). 
Interestingly, TG2 inhibition can sensitise drug-resistant cells to anti-cancer drugs 
(Kim, et al., 2006; Kim, Park and Kim, 2009), though the precise mechanism of 
association between TG2 and drug resistant is not clearly understood.  
The aim of this chapter is therefore to investigate whether TG2 expression directly 
correlates with drug-resistant mechanism(s), in cisplatin-resistant HepG2 cell lines 
developed by a single-dose selection process.  
5.2 Results    
5.2.1 Drug selection and determination of inhibitory concentration  
HepG2 cells were selected because of their ease of maintenance in cell culture, high 
sensitivity to cisplatin, compared to other cell lines tested in our laboratory, and their 
high content of TG2 protein. To determine the inhibitory concentration of cisplatin at 
which 50% and 80% of cells stop growth for a selected time period, cells were 
exposed to 0-20 µM cisplatin for 24 and 48 hours. The cell growth was measured, 
using the cell counting kit-8 (CCK-8) viability assay and IC50 values of cisplatin for 24 
and 48 hours were calculated at 8 and 4 µM, respectively. The IC80 values of cisplatin 
for 24 and 48 hours were 20 and 8 µM, respectively (see figure 4.1 in chapter 4). The 
IC80 was confirmed by flow cytometric analysis (figure 5.1).  
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Figure 5.1 Confirmation of inhibitory concentration of cisplatin by flow 
cytometry.  
HepG2 cells were treated with 4 µM and 8 µM cisplatin for 24 and 48 hours. 
Then cells were analysed using the FITC-labelled Annexin V apoptosis 
detection kit by flow cytrometry. The p value was calculated by Student’s 
paired t- test.     
 
Loss of cell proliferation was continued for 4 days after removing cisplatin-containing 
media from the culture flasks that were treated with 8 µM cisplatin for  48 hours. The 
results indicate that a single higher dose of cisplatin may have long term cytotoxicity 
and side effects on healthy cells. This effect was evaluated by observing cells under 
the inverted light microscope after regular 12 hours intervals for 4 days.       
 
5.2.2 Characterisation of drug-resistant cells and determination of fold 
resistance    
5.2.2.1 Morphological characteristics of HepG2 cells and HepG2/cr cells    
Using methods of a single dose exposure to 8 µM cisplatin (IC80 value at 48 hours) 
over a period of 0 to 4 days, cisplatin-resistant sublines of sensitive HepG2 cell lines 
were successfully selected. Then, cells were freed of cisplatin-containing medium and 
incubated for a further 4 weeks to recover from drug shock, replacing cisplatin-free 
fresh media every two days. Subsequently, cell colonies were isolated and frozen-
down in liquid nitrogen. One flask was left untreated as a control, but was passaged 
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as long as treatment lasted. It is very important to passage the control cells alongside 
the drug treated cells, because continuously-cultured cells can alter their 
characteristics, including drug resistance (McDermott, et al., 2014).  
  
  
Figure 5.2 Morphology of parental and drug-resistant cells. 
HepG2 cells were incubated with single dose of 8 µM cisplatin continuously for 4 
days. After incubation, cells were incubated with cisplatin-free medium for another 4 
weeks and during that time cells’ morphologies were observed using inverted phase 
contrast microscopy. (A) Parental HepG2 cells before treatment, (B) Cisplatin-
resistant cells (HepG2/cr) recovered from drug resistant colonies, (C) Time-
dependent observation of parental cells during development of resistance to cisplatin. 
Day 4, Day 14 and Day 28 indicate cells growing in culture media (cisplatin-free) after 
end of cisplatin treatment. The magnification of figure A & B is x100 whereas x40 for 
remaining. Images were taken using iPhone 5 camera. Scale bar = 12.45 µm. 
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Viable cell colonies surviving from cisplatin treatment were established and named 
as the HepG2/cr cell line. Drug resistant cells (HepG2/cr) changed their morphology 
and growth features compared to parental cells, growing initially in spheroid colony 
form and then layering on each other, as observed by inverted phase contrast 
microscope (figure 5.2); the growth rate of resistant cells was slower than that of 
parental cells. Changes in resistance phenotype may occur due to daughter colony 
formation. After comparing results with the available literature (Lopez‐Ayllon, et al., 
2014), it was found that drug-resistant cells appeared to grow morphologically like 
tumour stem cells, however, specific biomarker analysis for stem cells would be 
required to confirm this stem cell-like phenotype. Although the shape of drug resistant 
cells reverted back to that of parental cells after a number of passages (5 passages); 
the initial growth rate of these cells was still slow when cells were resuscitated from 
liquid nitrogen, compared to parental cells.  
5.2.2.2 Cisplatin sensitivity decreased in single dose-treated cisplatin-
resistant cells    
To determine the cisplatin sensitivity of HepG2/cr, cells were grown in cisplatin-free 
medium and then exposed to 0-20 µM cisplatin for 24 and 48 hours. The results 
indicated that the cells that survived a single dose of cisplatin were less sensitive to 
subsequent cisplatin treatment. The drug sensitivity of cisplatin in HepG2/cr cells was 
decreased from 8 µM to 18 µM (IC50 values) after 24 hours and from 4 µM to 12 µM 
(IC50 values) after 48 hours compared to parental cells (figure 5.3A and B).  
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Figure 5.3 Determination of cisplatin sensitivity in HepG2/cr cells. 
Drug resistant phenotypes were measured by incubating HepG2 and HepG2/cr cells 
with final concentrations of 0-20 µM cisplatin for 24 hours (A) and 48 hours (B) and 
cell viability was measured and calculated by CCK-8 assay. Results are mean ±SD 
of triplicate of three independent experiments. The p value was calculated by 
Student’s paired t- test.   
 
HepG2/cr cells were also exposed to 8 µM cisplatin for 24, 48 and 72 hours and the 
cells’ response to cisplatin was determined by CCK-8 cell viability assay. Interestingly, 
in the presence of cisplatin, growth rate of cisplatin-resistant HepG2/cr cells was 
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higher (90% viable cells) compared to parental cells (50% viable cells), while the 
proliferation rate was similar in both cell types (figure 5.4).      
 
  
Figure 5.4 Time course analysis of HepG2 and HepG2/cr cells in 
presence of cisplatin.   
HepG2 and HepG2/cr cells were grown in the presence or absence of 8 µM 
cisplatin for various time points and cell growth was measured and calculated 
using the CCK-8 viability assay.     
 
 
5.2.3 Cisplatin-resistant cells showed no cross-resistance to other anti-
cancer drugs  
Most of the cell lines used for cisplatin resistance studies have induced cross-
resistance to different anti-cancer drugs, when used in combination with cisplatin 
(Zhou, et al., 2010). To find out whether single-step selected drug-resistant HepG2/cr 
cells have a cross-resistant phenotype, Doxorubicin and 5-Fluorouracil were used to 
test for cross-drug- resistance. The HepG2/cr and HepG2 cells were incubated with 
0-100 µM 5-Fluorouracil and 0-5 µM Doxorubicin for 48 hours. Notably, no significant 
cross-resistance was observed with Doxorubicin and 5-Fluorouracil (figure 5.5).   
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Figure 5.5 Determination of cross-resistance to other anti-cancer 
chemotherapeutic drugs. 
Potential cross-resistance to doxorubicin and 5-fluorouracil was observed by 
CCK-8 viability assay. HepG2 parental and HepG2/cr cells were incubated 
with final concentrations of 0-5 µM doxorubicin (A) and 0-100 µM 5-fluorouracil 
(B) for 48 hours. The results are means ±SD of triplicate of three independent 
experiments.   
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5.2.4 Cell migration of drug resistant cells is increased compared to 
parental cells  
Cell migration (metastasis) is one of the hallmarks of cancer cells. When cancer cells 
become drug resistant, they also become more prone to metastasis (Hanahan and 
Weinberg, 2011). To investigate the characteristics of drug-resistant cells, wound 
scratch assays were performed. Figure 5.6 indicates that after 12 hours, drug 
resistant cells had started migrating and had filled the wound gap after 24 hours, 
whereas parental cells took 48 hours to migrate to fill the wound area completely.               
  
  
    
Figure 5.6 Cell migration analysis of parental and resistant cells  
Cells (4x105 cells/well) were grown in 12-well culture plates. After 24 hours, a 
wound boundary was created using 10 µl pipette tip. Then cells were washed 
twice with fresh culture media and incubated at 37 oC for further analysis. 
Images were taken using an inverted phase contrast microscope, at x100 
magnification.    
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5.2.5 TG2 mRNA and protein expression is reduced, but TG2 activity is 
increased, in cisplatin-resistant cells     
The overexpression of TG2 has been observed during development of drug-
resistance in cancer cells in many studies of multi-dose treated cells (Verma, et al., 
2006; 2008). To determine whether TG2 expression directly correlates with drug-
resistance, TG2 mRNA expression, protein expression and transamidation activity 
were measured in HepG2/cr cells and compared to these measurements in HepG2 
parental cells (see figure 5.7).  
 
92 
 
  
Figure 5.7 Comparison of TG2 expression in parental and cisplatin-
resistant HepG2 cells.  
(A) Western blot analysis of TG2 protein expression. Equal numbers (1x106 
cells) of HepG2 and HepG2/cr cells were lysed in cell lysis RIPA-buffer and 
Western blotting was performed using an anti-TG2 polyclonal antibody raised 
in the rabbit. (B) TG2 gene expression at the mRNA level was measured by 
RT-PCR, (C) TG2 transaminase activity was measured by specific TG2 
colorimetric assay kit. All the results are means ±SD of triplicate experiments. 
The p >0.05. Rh TG2 denotes recombinant human TG2 protein.         
 
The HepG2/cr cells showed very low TG2 mRNA gene expression and this reflected 
the TG2 protein level, which was also lowered compared to parental cells (figures 
5.7A and B). However, and in direct contrast to its level of expression, TG2 
transamination activity was increased in drug-resistant HepG2/cr cells compared to 
parental cells (figure 5.7C).     
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5.2.6 Cisplatin treatment increased TG2 gene expression and 
transaminase activity in cisplatin-resistant HepG2/cr cells  
As observed previously in chapter 4, cisplatin modulates TG2 expression in HepG2 
cells. To find out whether TG2 is expressed in a similar pattern in drug-resistant cells, 
HepG2/cr cells were treated or not-treated with 0-16 µM cisplatin for 24 hours. 
  
Figure 5.8 TG2 expression in HepG2/cr cells after cisplatin treatment  
HepG2/cr cells were treated with 0-16 µM cisplatin for 24 hours. Then: (A) TG2 protein 
expression was measured by Western blotting; (B) TG2 gene expression at the 
mRNA level was measured by RT-PCR and PCR products were observed by 1.2% 
agarose gel electrophoresis; (C) TG2 transaminase activity was measured using 
specific TG2 colorimetric assay kit. The p value was calculated using Student’s paired 
t-test (B) and One Way ANOVA with Dunette’s multiple comparison test (C). Rh TG2 
denotes recombinant human TG2 protein.      
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When cells were treated with 8 µM cisplatin, TG2 mRNA expression was increased 
in HepG2/cr cells compared to parental HepG2 cells (figure 5.8B). However, Western 
blot analysis of 0-16 µM cisplatin-treated cells showed no difference in TG2 protein 
expression between cisplatin-treated and untreated groups (figure 5.8A). TG2 
enzymatic activity however was increased upon cisplatin treatment over a period of 
24 hours (figure 5.8C). This increase in TG2 enzymatic activity may reflect a role for 
TG2 activity during cellular trafficking of anti-cancer drugs in chemoresistant cells, 
where it may reduce or block the flow of cisplatin across the plasma membrane (see 
figure 6.3 in chapter 6).   
5.3 Discussion        
Different cisplatin-resistant cell lines have been developed (McLaughlin, et al., 1991; 
Zhou, et al., 2010; Gumulec, et al., 2014) to elucidate the mechanisms and important 
key proteins and enzymes underlying its effects. Cisplatin-resistant sub-lines of the 
sensitive HepG2 cell line were developed by a single-dose treatment with cisplatin 
similar to that previously developed in a human ovarian cancer cell line (McLaughlin, 
et al., 1991), and a lung cancer cell line (Lopez‐Ayllon, et al., 2014). Results from this 
study indicate that the cisplatin-resistant cells changed their shape and were less 
sensitive to cisplatin, as analysed by time-course incubation studies (figures 5.3 and 
5.4). The drug resistant phenotype was increased by 2.25 fold at IC50 level in cisplatin-
resistant cells. Apart from the molecular mechanism, presence of stem cells is 
considered to be responsible for chemoresistance (Tomuleasa, et al., 2010). This 
study observed morphological characteristics of stem cells in these drug-resistant 
cells (figure 5.2). However, no specific biomarker (e.g., CD133 (prominin-1), an apical 
plasma membrane protein (Romano, et al., 2015)) study of cancer stem cells was 
performed because of the cost of the reagents. The drug-resistant cells were not 
cross-resistant to doxorubicin and 5-fluorouracil (figure 5.5), suggesting an 
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independent mechanism for cisplatin resistance. Cell migration rate was increased in 
cisplatin resistant cells (figure 5.6).  
Cancer cells tend to have higher TG2 expression and activity than normal cells and 
this may contribute to their chemo-resistance. Following the characterisation of 
cisplatin-resistant cells, the TG2 expression profile was investigated in these cells. 
The findings from this study have created new insights into the TG2 expression 
pattern in drug-resistant cells, in which TG2 expression decreased but activity 
increased in cisplatin resistant cells (figure 5.7).  Interestingly, TG2 mRNA expression 
increased upon subsequent cisplatin treatment in these resistant cells (figure 5.8B), 
which indicates the spatial pattern of TG2 expression and accumulation, when cells 
come in contact with anti-cancer drug upon multiple dose treatment, which may help 
cancer cells to become highly drug-resistant and reduce cisplatin sensitivity.  
Overexpression of glutathione-s-transferase (GST) is one of the conditions of 
chemoresistant cells that is found to involve in reducing activity of anti-neoplastic 
drugs (Townsend and Tew, 2003; Balendiran, Dabur, and Fraser, 2004). As a control 
experiment, the expression of GST was measured in both cell lines. Results 
consistent with previous findings showed that the GST expression was increased in 
cisplatin resistant cells compared to parental cells, though there was no significant 
difference in GST level when compared between both cell lines (see figure I.6 in 
appendix I).         
Collectively, these results suggest that shortly after initial treatment of HCC cells with 
cisplatin, increased TG2 transamidating activity contributes to the cells development 
of chemoresistance.  From this study, it is also predicted that the detection of the level 
of TG2 activity at biopsy, shortly after initial treatment with cisplatin, could be used to 
predict a patient’s likelihood of subsequently developing drug resistance.  
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CHAPTER 6: 
6. TRANSGLUTAMINASE 2 IN CELLULAR UPTAKE OF THE ANTI-
CANCER DRUG CISPLATIN IN HEPATOCARCINOMA CELLS      
6.1 Introduction  
As observed in chapter 5, TG2 transamination activity is increased in drug resistant 
HepG2 cells. As a result of such observations, by modulating its expression, this 
chapter investigates the role of TG2 in the cellular uptake of fluorescent-labelled 
cisplatin.   
Cells live and grow by exchanging molecules within their local environment. The 
exchange of molecules is controlled at the plasma membrane, which acts as a barrier 
to transit molecules into and out of the cell. These processes are carefully controlled 
in many ways, through a variety of membrane transport mechanisms (Alberts, et al., 
2013).  
Studies have shown that many drug molecules, including cisplatin, are passively 
transported across plasma membrane against their lipophilicity (Dobson and Kell, 
2008). Several lines of evidence on drug resistant cell lines have shown that the 
anticancer drugs that enter cancer cells depend upon specific mechanisms of carrier-
mediated transport and that this process may be modified in drug-resistant cancer 
cells, though the cellular pathway of drug uptake, including for cisplatin, is not yet 
clearly defined (Mellman and Yarden, 2013).  
The blockade or modification of cellular uptake mechanisms at the plasma membrane 
can cause failure of cellular uptake of anti-cancer drugs by cancer cells, which is one 
of the major challenges in the successful treatment of cancer by chemotherapy. 
Therefore, an understanding of the mechanisms that control cellular uptake of ligands 
is crucial in the development of effectiveness of drugs, specifically against drug-
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resistant cancer cells. To date, several lines of evidence support a role for TG2 
involvement in receptor mediated endocytosis (Davies, et al., 1980; Schrier and 
Junga, 1981; Ray and Samantha, 1996; Abe, et al., 2000), though until now, no 
reports have specifically investigated TG2 involvement in endocytosis of anti-cancer 
drugs such as cisplatin in hepatocarcinoma cells.              
The aim of this chapter is therefore to investigate whether the presence of TG2 is 
involved in cellular uptake of cisplatin, both in parental and drug-resistant cells. First, 
the pilot study was conducted on the uptake of a non-toxic fluorescence probe, 
dansylcadaverine, in parental cells (see section 3.3.2). Then, fluorescently-labelled 
cisplatin was used to investigate the role of TG2 in cellular trafficking of the anti-
cancer drug cisplatin in HepG2 cells and its involvement in drug-resistance in a model 
of HCC.  
6.2 Results and discussion   
6.2.1 Alexa fluor 546 labelled-cisplatin uptake is reduced in cisplatin-
resistant cells   
Single dose cisplatin-resistant HepG2 cells were developed (section 5.2.2), and the 
accumulation or uptake of Alexa fluor 546-labelled cisplatin in both parental HepG2 
and cisplatin-resistant HepG2/cr cells was analysed by confocal microscopy. Both 
cell lines were grown in 4-well glass Lab-Tek chamber slides and incubated with 
Alexa fluor 546-labelled cisplatin, at a final concentration of 200 U/ml. Following 1 
hour of incubation, Alexa fluor cisplatin was visible in the nucleus of cells, with a finely 
granular pattern, and was seen to be distributed throughout the cytoplasm and 
nucleus in the majority of parental HepG2 cells, whereas in cisplatin-resistant 
HepG2/cr cells, the Alexa fluor cisplatin was seen to be present only on the plasma 
membrane (figure 6.1A).  
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Figure 6.1 Cellular fluorescence distribution following uptake of Alexa fluor 
546/488-labelled cisplatin. 
(A) HepG2 and single-step selected cisplatin-resistant HepG2/cr cells were incubated 
with Alexa fluor 546-labelled cisplatin at a final concentration of 200 U/ml for different 
time periods. Then cells were washed with PBS, fixed with 70% ethanol, mounted in 
fluorescent mounting medium and observed under a laser scanning confocal 
microscope at x400 magnification with excitation/emission at 543/530nm. Scale bar 
= 0.44 µm. Results are representative of triplicate experiments. (B) Cellular uptake of 
alexa fluor 488-labelled cisplatin measured by flow cytometry. Approximately 5 x 105 
cells were incubated with Alexa fluor 488-labelled cisplatin at a final concentration of 
40 U/ml in 6-well culture plate for different time points. Then cells were collected, 
washed with PBS and re-suspended in ice-cold PBS. Then 10,000 cells were 
analysed immediately by flow cytometry with fluorescence intensity detector filter set 
at FL-1 (FITC). Results are ±SD of triplicate experiments.      
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The defective cellular uptake of Alexa fluor cisplatin in cisplatin-resistant cells was 
also measured by flow cytometry. Approximately 500,000 cells were incubated with 
Alexa fluor 488-labelled cisplatin at a final concentration of 40 U/ml for up to 2 hours. 
The results were consistent with the confocal microscopic analysis; since as 
incubation time increased, the fluorescence intensity was lower in cisplatin-resistant 
cells compared to parental cells (figure 6.1B).    
6.2.2 Localisation of TG2 during cellular uptake of fluorescent labelled 
cisplatin  
The pattern of TG2 expression during uptake of Alexa fluor 546-labelled cisplatin in 
both cell lines was observed by immunofluorescence analysis (see section 2.20). 
Results shown that there was no difference in TG2 expression at the protein level, 
consistent with the results shown in figure 5.8A (figure 6.2).  
 
Figure 6.2 Analysis of TG2 expression during cellular uptake of fluorescent 
cisplatin  
HepG2 and HepG2/cr cells were treated with Alexa fluor 546 labelled-cisplatin and 
the expression of TG2 in the cytoplasm and the nucleus were observed using an anti-
TG2 antibody by immunofluorescence. The slides were observed using a DMR-X 
fluorescence microscope, at x200 magnification. Scale bar = 25 µm.   
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To determine whether there was change in TG2 expression pattern, in different 
cellular compartments, cisplatin was applied to both cell lines. However, interestingly, 
Western blot analysis of separated cell fractions showed that treatment of normal and 
chemo-resistant cells with 8 µM cisplatin for 24 hours caused alterations in the 
location of TG2 isoforms and the patterns of Alexa fluor 546-labelled cisplatin uptake. 
Initially, TG2-L was seen to be exclusively located in the cytoplasm and TG2-S was 
predominantly localised in the plasma membrane of both cell lines (figures 6.3A and 
B).  
  
Figure 6.3 Localisation of TG2 during cellular uptake of cisplatin.  
HepG2 and HepG2/Cr cells were treated or not-treated with 8 µM cisplatin for 24 
hours. Then cytoplasmic and membrane-associated proteins were extracted with a 
commercially-available membrane preparation kit. The TG2 expression was 
measured in (A) parental HepG2 and (B) chemoresistant HepG2/cr cells by Western 
blotting. WL = whole lysate, Cyto = Cytoplasm, Memb = Membrane. The anti-TG2 
antibody (raised in mouse, cat. no. ab2368) used in this analysis was different to that 
used in chapter 4 and 5, as this antibody can bind to both TG2 isoforms.    
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Following cisplatin treatment of normal cells, TG2-S was lost from the plasma 
membrane and appeared to relocate to the cytoplasm (figure 6.3A); an effect not seen 
in chemo-resistant cells (figure 6.3B). 
6.2.3 TG2 inhibition by cystamine increased uptake of Alexa fluor 488-
labelled cisplatin  
As observed in Chapter 5, TG2 transamidation activity was increased in cisplatin-
resistant cells compared to parental cells. To investigate whether inhibition of TG2 
activity influences changes in cellular uptake of cisplatin, parental HepG2 and 
cisplatin-resistant HepG2/cr cells were pre-incubated with the TG2 inhibitor, 
cystamine, at a final concentration of 2 mM for 48 hours. Then, cells were incubated 
with 40 U/ml of Alexa fluor 488-labelled cisplatin for up to 2 hours and fluorescent 
uptake of cisplatin into cells was measured by flow cytometry.  
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Figure 6.4 Inhibition of TG2 activity increased the uptake of fluorescent 
cisplatin in both cell lines.  
(A) The parental HepG2 and cisplatin-resistant HepG2/cr cells were treated 
or not-treated with the TG2 inhibitor, cystamine, at a final concentration of 2 
mM for 48 hours. TG2 activity was measured by TG2-specific colorimetric 
assay kit. (B) The cystamine pre-treated cells were incubated with Alexa fluor 
488-labelled cisplatin to a final concentration of 40 U/ml for up to 2 hours. The 
cells were collected by centrifugation, washed with PBS and then 
fluorescence intensity was measured by flow cytometry with fluorescent 
intensity detector filter set at FL-1 (FITC). Results are mean ±SD of triplicate 
experiments.  
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The results indicate that the cystamine treatment decreased the TG2 transamidation 
activity (figure 6.4A), and significantly increased the accumulation or uptake of 
fluorescent cisplatin in both cell lines (figure 6.4B). Quantitatively, the level of uptake 
of fluorescent cisplatin was increased by approximately 50% in cystamine-treated 
cells compared to non-treated cells. Cystamine treatment did not affect cell viability 
(see section 4.2.9).            
6.2.4 TG2 gene silencing increased uptake of Alexa fluor 488-labelled 
cisplatin   
To determine whether TG2 mRNA knockdown increases the uptake of fluorescently-
labelled cisplatin, as observed in cystamine treatment, a TG2-specific siRNA oligomer 
was delivered using Lipofectamine2000 transfection reagent.  After 48 hours, TG2 
expression was measured by Western blotting, and remaining cells were incubated 
with Alexa fluor 488-labelled cisplatin at a final concentration of 200 U/ml for 1 hour, 
and 40 U/ml for up to 2 hours, for confocal microscopy and flow cytometry analysis, 
respectively. Figure 6.5A indicates that mRNA silencing was effective and TG2-L was 
effectively eliminated from both sensitive and chemo-resistant cells. The cellular 
uptake effect was time-dependent, with similar patterns at the two time points, but 
greater effect being seen after two hours compared to one hour incubation, in parental 
cells (figure 6.5B).    
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Figure 6.5 Cellular uptake of Alexa fluor 488-labelled cisplatin after TG2 
mRNA silencing measured by flow cytometry  
(A) Western blot showing reduction of TG2 expression after siRNA treatment 
for 48 hours. (B) Cellular uptake of fluorescent cisplatin after siRNA treatment. 
Parental and resistant cells were pre-treated with, or without siRNA specific 
for TG2 mRNA for 48 hours and then cells were incubated with Alexa fluor 
488- labelled cisplatin to a final concentration of 40 U/ml for up to 2 hours. 
Then cells were harvested by trypsinisation, suspended in ice-cold PBS and 
fluorescence intensities were measured by flow cytometry with fluorescent 
detector set at FL-1 (FITC). The results are ±SD of triplicate experiments.  
 
The short form (TG2-S) however was not fully eliminated from cells, although its 
expression appeared much reduced in both cell lines, which showed only a trace of 
TG2-S (figure 6.5A). This incomplete removal of TG2-S from cells may explain the 
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pattern of uptake of cisplatin when control cells are compared to TG2 knockdown 
cells (figure 6.5B).  
  
 
  
Figure 6.6 Cellular uptake of Alexa fluor 488-labelled cisplatin after TG2 
mRNA silencing analysed by confocal microscopy   
TG2 expression of HepG2 and HepG2/cr cells was reduced using specific 
TG2 siRNA oligomer for 48 hours and then cells were incubated with Alexa 
fluor 488-labelled cisplatin at a final concentration of 200 U/ml for 1 hour. Then 
cells were fixed in 70% ethanol at -20 oC and mounted in fluorescent mounting 
medium. The slides were observed under a laser scanning confocal 
microscope at x400 magnification with excitation/emission wavelengths set at 
488/530 nm. Scale bar = 0.44 µm.      
  
The pattern of expression suggests that TG2-L knockdown increases cisplatin uptake 
in both cell lines, as the fluorescent intensity was greater in siRNA-treated cells 
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compared to non-treated (control groups) in both cell lines. In siRNA-treated cells, 
fluorescent cisplatin was visible in the nucleus of both cell lines, whereas fluorescent 
cisplatin was not seen in siRNA non-treated (control group) HepG2/cr cells (figure 
6.6).   
6.3 Conclusion   
These results suggest that the presence of TG2 either in the cell membrane or 
cytoplasm reduced the trafficking of anti-cancer drug cisplatin in cisplatin-resistant 
cancer cells and that its inhibition may provide a novel mechanism to overcome the 
defective uptake of anti-cancer drugs in other chemotherapy-resistant cancers. TG2 
may possibly be of use as a biomarker of defective cellular uptake or endocytosis in 
clinical tumour chemotherapy. 
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CHAPTER 7: 
7. IMMUNOPRECIPITATION OF TRANSGLUTAMINASE 2 
SUBSTRATES DURING CELLULAR UPTAKE OF 
DANSYLCADAVERINE    
7.1 Introduction  
The purpose of this chapter is to validate anti-dansyl antibody so that this antibody 
can be used to immunoprecipitate DNC-labelled proteins, which have been modified 
by TG2 during cellular uptake of DNC in HepG2 cells, as discussed in chapter 3. For 
this purpose, first the catalytic action of TG2 was confirmed using pepsin as a model 
substrate for transamination reaction. Pepsin was used as it was commercially cheap, 
and its complete crystal structure was available, and modification sites are relatively 
easy to predict. Previously researchers have used pepsin for such kind of studies but 
using putrescine as an amine donor (Coussons, et al., 1992b). Also studies on pepsin 
modification will contribute to better understand TG2 substrate specificity. Once 
confirmed following pepsin modification study that DNC-labelled pepsin can be 
isolated and visualised by immunoprecipitation using anti-dansyl antibody, the same 
antibody was used to immunoprecipitate DNC-labelled proteins from cell lysate that 
had been treated with DNC.      
TG2 has been implicated in the control of several physiological processes by 
modifying substrate proteins. As observed in chapters 3 and 6, the presence of TG2 
has implications in the mechanism of cellular uptake of dansylcadaverine and 
cisplatin, respectively, in HepG2 cells. Therefore, the tendency of TG2 to modify 
proteins during cellular uptake of DNC was investigated. HepG2 cells were treated 
with DNC and the DNC-labelled proteins were then immunoprecipited and 
characterised according to their molecular weight by SDS-PAGE. Initially, 
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immunoprecipitation and TG2 activity assays were developed using pepsin as a 
model substrate protein and DNC as an amine donor (see below).        
7.1.1 Pepsin as a model substrate for TG2  
Pepsin is a well-known gastric protease that catalyses the breakdown of the 
polypeptide chain of proteins into smaller peptides under physiological conditions. 
Detailed information is available on its complete structure (Tang, et al., 1973; Cooper, 
et al., 1990). Previously, Waelsch reported that pepsin can be a candidate substrate 
of transglutaminase (Mycek and Waelsch, 1960). With the help of identified predictor 
amino acids (Khew, et al., 2010), pepsin was examined and predicted as a substrate 
protein for transglutaminase and this was confirmed experimentally in vitro. The 
modification of pepsin by guinea pig liver transglutaminase is shown in figure 7.1.  
 
Figure 7.1 Illustration of the pepsin modification reaction catalysed by 
transglutaminase. 
The amine group of glutamine residue of pepsin may be replaced with 
dansylcadaverine by transglutaminase enzyme activity in the presence of Ca2+. The 
product of this reaction is a dansylcadaverine-labelled glutaminyl residue of pepsin. 
 
The action of TG2 activity was investigated using DNC as an amine donor and porcine 
pepsin as an amine acceptor, to establish the subsequent experiments that can be 
performed in cellular environment to characterise and isolate DNC-labelled proteins, 
which may have been modified by the action of TG2, during cellular uptake of drugs 
(i.e., DNC and cisplatin), to better understand the physiological roles of TG2 in the 
mechanism of membrane transport of compounds/drugs.  
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7.2 Results 
7.2.1 Measurement of absorbance spectrum of dansylcadaverine  
In order to quantitate DNC, the molar absorbance coefficient was determined. The 
absorbance maximum of dansylcadaverine (DNC) was identified by measuring the 
optical density of DNC in a 1 cm cuvette at various wavelengths. Figure 7.2 shows 
the absorbance spectrum of DNC; it indicates that the maximum fluorescence 
absorbance of DNC was obtained at a wavelength of 330 nm.  
 
Figure 7.2 Measurement of absorbance spectrum wavelength of DNC. 
Absorbance of 1 ml of DNC (1 mM) in 1 cm cuvette was measured at 
wavelengths of 310-370 nm.   
 
7.2.2 Analysis of DNC-labelled pepsin by HPLC  
To characterise the TG2 activity for subsequent experimental groups, the 
susceptibility of porcine pepsin to the action of guinea pig liver transglutaminase was 
tested by measuring the Ca2+-dependent incorporation of the primary amine 
dansylcadaverine (DNC). Pepsin was deactivated by incubating the samples at pH 
8.0 and the stock solution was stored at 4 oC for 24 hours, at pH 8.0 prior to the 
modification reaction. The deactivated pepsin was then incubated with DNC and Ca2+ 
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in the presence or absence of guinea pig liver transglutaminase for up to 24 hours at 
RT. 
The modification of pepsin was first confirmed by isolating samples by HPLC using a 
C18 column (see section 2.26). The samples with modified pepsin were collected and 
measured using a UV detector set at 215 nm. As the incubation time was increased, 
more pepsin was labelled with DNC. In figure 7.3B, the second peak represents non-
modified pepsin, whereas in figures 7.3C-G, the second peak represents the modified 
pepsin with DNC. Results indicate that as incubation time increased, the second peak 
increased in size (figures 7.3C-G).    
 
 
Figure 7.3 Elution profile of dansylcadaverine-labelled pepsin by HPLC. 
Pepsin was incubated with dansylcadaverine in the presence or absence of guinea 
pig liver transglutaminase for different time intervals, and 100 µl from reaction 
mixtures were taken out at different time points and separated by HPLC. (A) Blank 
reaction (no pepsin and no transglutaminase), (B) control (only pepsin), (C) 1 hour, 
(D) 2 hour, (E) 5 hours, (F) 10 hours, and (G) 24 hours. All the graphs (except A and 
B) shown here are products of reaction in presence of transglutaminase and 
absence of EDTA.  
 
111 
 
7.2.3 Analysis of TG2 activity by DNC-incorporation into pepsin by gel 
filtration chromatography  
Following TG2 catalysed modification of pepsin (see section 2.24), the dansylated-
pepsin was isolated by gel filtration chromatography using a PD-10 sephadex G-25 
column. Then, absorbance of eluted samples was measured at 330 nm, at which the 
dansyl group gives maximum fluorescence. 
  
Figure 7.4 Elution profile of dansylcadaverine labelled pepsin of gel 
filtration on PD-10 Sephadex G-25 columns.   
The samples (A) in the absence of transglutaminase, (B) in the presence of 
transglutaminase were prepared and the reaction mixtures after 24 hours of 
incubation were separated by gel filtration chromatography. The absorbance 
of eluted samples (1 ml each in separate tube) was measured at 330 nm. No 
of tubes on x-axis indicates the 1 ml samples in each single tube. Results 
are representative of triplicate experiments.       
 
The first peak in figure 7.4B indicates that the DNC-labelled pepsin has increased 
absorbance at A330 compared to non-modified pepsin (figure 7.4A). These results 
confirm earlier reports that porcine pepsin can be modified by transamination reaction 
by transglutaminase enzyme (Coussons, et al., 1992b).   The second major peak 
represents non-covalently bound, i.e., free DNC. 
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7.2.4 Time-dependent incorporation of dansylcadaverine into pepsin by 
guinea pig liver transglutaminase  
The quantitative analysis of DNC-labelled pepsin was performed by measuring the 
optical density of eluted samples at 330 nm at various time intervals.  
 
Figure 7.5 Time dependent incorporation of dansylcadaverine into 
pepsin. 
Time-dependent incorporation of dansylcadaverine into pepsin by guinea pig 
liver transglutaminase (gpTgase). Pepsin was incubated with gpTgase in the 
presence or absence of EDTA for various time points.   
 
Figure 7.5 shows that as the incubation time increased, more DNC was incorporated 
into pepsin. In the presence of EDTA no DNC was incorporated. The results show 
that 0.25 mol of DNC was incorporated per 34 kDa subunit of pepsin . Previous 
studies, using the less bulky substrate putrecine, suggest that up to 1 mol/mol 
incorporation is possible in non-reduced sample of pepsin, suggestive of a single 
reactive strand in the protein (Coussons, et al., 1992b). Evidence of high molecular 
weight  (Mr) material in Coomassie stained gels indicate that cross-linking of pepsin 
occurs, which probably explains < 1 mol/mol DNC-pepsin incorporation (see figure 
7.7).     
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7.2.5 Western blotting showed pepsin labelled with dansylcadaverine  
The pepsin was labelled with DNC by Tgase for up to 24 hours (section 7.2.2, 7.2.3, 
7.2.4) and the resulting products were analysed using SDS-PAGE and by inspecting 
gels under ultraviolet fluorescent (UV) light (figure 7.6A).  
 
Figure 7.6 Western blot of dansylcadaverine-labelled pepsin. 
(A) Inspection of a gel in UV fluorescent light before transferring to nitrocellulose 
membrane, (B) Western blot of modified pepsin detected by anti-dansyl antibody. 
Lanes 1-7 represent the samples in the presence of Tgase incubated for different 
period: Lane 1 - Negative control (EDTA was added to reaction mixture; sample 
loaded is from 24 hours incubation); lane 2 - 0 hour; lane 3 - 1 hour; lane 4 - 2 
hours; lane 5 - 5 hours; lane 6 - 12 hours; lane 7 - 24 hours; lanes 8-13 represent 
the samples in the absence of Tgase, lane 8 - 0 hour; lane 9 - 1 hour; lane 10 - 2 
hours; lane 11 - 5 hours; lane 12 - 12 hours; lane 13 - 24 hours. Lanes described 
represents both diagrams. Results are representative of three independent 
experiments. 
 
The pepsin became increasingly fluorescent as a function of incubation time (figure 
7.6A, lanes 1-7), whereas no visible bands were observed in the presence of EDTA 
and/or when Tgase was omitted from mixtures (figure 7.6A, lanes 8-13).  
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Figure 7.7 SDS-PAGE of modified pepsin.  
Only DNC-labelled pepsin samples were seperated on 12% SDS-PAGE gel, as 
apposed to non-labelled pepsin samples. Lanes represent the samples taken at 
different periods of incubation. Lane 1 - control (only pepsin); lane 2 - 0 hours; lane 
3 - 1 hour; lane 4 - 2 hours; lane 5 - 5 hours; lane 6 - 10 hours; lane 7 - 24 hours.       
 
The Coomassie staining of this gel showed effectively no changes of the protein band 
pattern of labelled pepsin (figure 7.7), in contrast to the bands observed under UV. 
Western blot analysis confirmed that there was increasing pattern of pepsin 
modification (figure 7.6B). 
7.2.6 Preliminary structural characterisation and identification of 
pepsin as a candidate protein substrate  
In order to investigate the substrate preference of TG2, pepsin was used as a model 
substrate protein, as its pure form is commercially available in relatively large 
quantities at reasonable cost and because the complete crystal structure is known 
(Tang, et al., 1973; Cooper, et al., 1990). The online ExPASY bioinformatics search 
engine was used to access the amino acid sequence of porcine pepsin and thus 
develop a model for prediction of available modification sites. The available scientific 
research articles were used to find out the complete structure of pepsin and the 
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TRANSDAB wiki (http://genomics.dote.hu/wiki/index.php/Main_Page) (Csosz, Mesko 
and Fesus, 2009) tool was used to find out the list of existing Tgase substrates. The 
primary amino acid sequence of pepsin and alignment of glutamine residues is shown 
in figure 7.8.  
 
Figure 7.8 Prediction of glutamyl residues in primary structure of pepsin. 
Possible reactive glutamine residues (shown in red) for transamidation reaction 
extracted from the primary structure of pepsin. Out of these, two glutamine residues 
(Gln-278 and Gln-309 ) were selected by applying the rules described in Table 1.1.  
 
On the basis of rules as described in Table 1.1 in the introduction (see section 1.5), 
two short peptides of amino acid residues SAYILQDDDSC (Gln-278) and 
DVFINQYYTVF (Gln-309) were predicted as possible Tgase modification sites in 
pepsin (figure 7.8). The predicted glutamine residues were from the C – terminus end 
of pepsin.   
7.2.7 Characterisation of cellular proteins during cellular uptake of 
dansylcadaverine in HepG2 cells  
It was confirmed from the Western blot of DNC-labelled pepsin that DNC groups can 
cross-react with anti-dansyl antibody (figure 7.6), before using the same antibody to 
immunoprecipitate DNC-labelled protein from cellular lysates. HepG2 cells were 
treated and total proteins were isolated following cell lysis; non-DSC treated cells 
were tested in parallel as controls (section 2.28). The results obtained showed that a 
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limited number of proteins were labelled with DNC following cellular uptake (figure 
7.9).  
 
Figure 7.9 Immunoprecipitation of DNC-labelled proteins from HepG2 
cells 
HepG2 cells were treated with different concentrations of DNC for 24 hours. 
Then, cell lysates were prepared using cell lysis RIPA buffer. To the 200 µl 
of cell lysates, 5 µg of anti-dansyl antibody were added and DNC-labelled 
proteins were isolated by immunoprecipitation. The DNC labelled proteins 
are indicated by the arrows.  
 
Following 24 hours’ incubation of cells with DNC, three DNC-labelled bands were 
observed with molecular weights of 102 kDa, 90 kDa, and 46 kDa. One of the bands, 
at 46 kDa, resembles the known molecular weight of TG2 substrate aldolase A, which 
has been previously identified as an intracellular substrate (Lee, et al., 1992). 
Aldolase A is known to generate extra energy for cancer cells; this drives cells 
towards cell proliferation and chemoresistance. If the modified protein is aldolase A, 
then TG2 may possibly inhibit energy generation in cancer cells by modifying aldolase 
and this could also impact on the inhibition of  cellular uptake of drugs. The other two 
bands were not close to the molecular weight of other identified intracellular TG2 
substrates, suggesting some new substrates of TG2 and these substrates may 
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possibly be involved during cellular uptake of drugs. Sequence analysis will be 
required to confirm whether the 46 kDa band found was actually aldolase A.    
7.3  Discussion  
The specificity of transglutaminase (Tgase) towards substrate proteins depends 
partly on the reaction conditions of the cellular environment. So far , more than 155 
substrates of TG2 have been identified (see appendix II) but none of these substrates 
give a clear consensus sequence regarding the substrate specificity of TG2.  
From the primary structure of pepsin, short peptides containing glutamine (fig 7.8) 
were analysed for possible reactive glutamine substrate of TG2. This was done by 
applying the predictive model, which distinguishes both encouraging and 
discouraging factors in potential substrates (Table 1.1). From the crystal structure and 
primary structure of pepsin (Tang, et al., 1973; Cooper, et al., 1990), it was clear that 
out of 14 glutamine residues, two glutamines were selected as possible reactive 
glutamines. The side chains of Gln-143, Gln-148 and Gln-255 were not significantly 
exposed to the solvent. By applying the charge rules, one of the discouraging 
characteristics for transglutaminase substrates specificity (Coussons, et al., 1992a), 
showed that the Gln-55 (Aspartate at -3, +4, +5), Gln-69 (Glutamate at -4), Gln-90 
(Aspartate at -3), Gln-99 (Aspartate at -3), Gln-191 (Aspartate at -4, Glutamate at -4), 
Gln-211 (Aspartate at +4), and Gln-267 (Aspartate at -3) would not act as substrates 
for modification because these peptides contain one of the amino acids that 
discourage enzyme specificity towards substrate. The residues Gln-25, Gln-233 and 
Gln-278 were ruled out as these residues contain more than one aspartic acid. Gln-
278 (SAYILQDDDSC) and Gln-309 (DVFINQYYTVF) (shown in 3D structure in figure 
7.10) were considered as possible reactive glutamine residues for modification by 
guinea pig liver transglutaminase, as these residues were exposed to the solvent and 
have accessibility of 0.67 which is a minimal requirement for transglutaminase-
catalysed modification. The two predicted reactive glutaminyl residues were from C-
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terminal sequences, and contained features that resemble other studies (Khew, et 
al., 2010).  
 
Figure 7.10 Prediction of glutamyl residues in three-dimensional stucture of 
pepsin.  
Position of possible glutamine residues (indicated by arrows) in three-dimensinal 
structure of pepsin. These two glutamine residues were selected by applying the 
substrate characteristics in primary structure of pepsin and are shown at particular 
positions (yellow arrow indicates Gln-278, and blue arrow indicates Gln-309). The 
three dimensional structure was created in ExPasy bioinformatics online tool.   
 
 
Quantitative analyses of DNC incorporated by transglutaminase indicate that pepsin 
has glutaminyl residues that are reactive for the transglutaminase reaction, and thus, 
further analysis by endoproteinase digestion and mass spectrometry of peptidyl 
fragments of DNC-peptides compared to control fragments would be required to 
validate these peptides as reactive residues. Also, further studies are needed to 
investigate whether glutaminyl residues of pepsin are an in vivo substrates and if so, 
what the role of TG2 in the regulation of pepsin’s functions?  The three DNC-labelled 
proteins isolated by immunoprecipitation following cellular uptake of DNC also need 
more analysis, e.g., by performing Mass spectrometric analysis.  
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In conclusion, the data presented here suggest that pepsin acts as a substrate of TG2 
and the discouraging factors described by Coussons et al (1992) and other 
researchers are somehow essential for the substrate specificity of TG2. The peptide 
residues predicted in this study will contribute to better understanding of in vivo Tgase 
transamidation activity and substrate specificity, and can be used as suitable probes 
to assess the endogenous activity of TG2, which is associated with various diseases 
including cancer. Three DNC-labelled proteins observed as TG2 substrates may 
serve very important functions during cellular uptake of anti-cancer drugs such as 
cisplatin in chemoresistant cancer cells.    
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CHAPTER 8:  
8. Discussion and future work  
8.1 Discussion    
Cisplatin, the so-called the “penicillin” of cancer (Cisplatin.org, 2017), remains an 
effective and extensively applied drug that is used to treat several types of cancer. 
Unlike other anti-cancer drugs, cisplatin is not restricted to licencing, and so is easily 
producible by any appropriately-validated company. However, chemoresistance to 
cisplatin, and toxicities to normal cells are major problems, but if this can be overcome 
it could again find a wider applicability. Thus, increasing cisplatin efficiency in cancer 
treatment could potentially save billions of pounds, and potentially many lives, which 
is worthy of investigation and this is the focus of the current study.  
During cisplatin therapy, patients are injected intravenously, with a bolus dose of 75-
100 mg/m2 of cisplatin every 3-4 weeks, or on a monthly basis, in multiple cycles 
(often 5 cycles), depending on the type of cancer (McDermott, et al., 2014). Cisplatin 
is often used in combination with other antineoplastic drugs, to achieve maximum 
effects. Some patients may respond very well to this therapy, whereas some may 
respond well at first, but relapse after subsequent treatment. In other patients, 
resistance may start after just an initial dose. Consequently, development of such 
resistance may require administration of higher dosages, which can lead to severe 
multiorgan toxicities. Results presented here are consistent with the clinical scenario, 
and show that a single shock treatment of the hepatocellular carcinoma HepG2 cell 
line with 8 µM cisplatin (relatively close to therapeutic plasma concentration, i.e. <2 
µg/ml (6.6 µM) 2 hours postadministration (McDermott, et al., 2014)), continuously for 
4 days, developed resistance to cisplatin (figures 5.2 and 5.3). The findings could be 
illustrative of how patients can develop cisplatin resistance after initial treatment, and 
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shows how a cancer cell can become aggressively more resistant following multiple 
cycles of chemotherapeutic treatment.  
It is well known that TG2 levels are raised in many cancers (Eckert, et al., 2015), 
though the specific effects that this has on neoplastic cells are not fully understood. 
In recent years there has been a suggestion that, in addition to roles in apoptosis and 
cell adhesion, TG2 may contribute in some way to chemotherapeutic resistance, as 
described in detail in the introduction (section 1.9.4.1), and this contention is the main 
theme for the current investigation. It has long been known that TG2 may be involved 
in endocytosis (Davies, et al., 1980) and so any alterations in this process could easily 
explain reduced uptake of chemotherapeutic drugs (Mellman and Yarden, 2013), if 
they were to enter cells by this route. The results herein show that TG2 transamination 
activity is increased in cisplatin-resistant HepG2 cells (figure 5.7). This increased TG2 
enzymatic activity suggests that TG2 may possibly cross-link cellular proteins and so 
inhibit apoptosis, and in that way may contribute to the development of drug 
resistance. This is in contrast to early studies on TG2, where researchers showed 
that extensive intracellular protein cross-linking by TG2 is required for induction of 
apoptosis (Fesus and Piacentini, 2002): this effects may be dependent on differences 
in cellular conditions and types of cell studied.     
A series of experiments (see sections 4.2.7-4.2.9) that investigated the relationship 
between TG2 levels and cell survival confirmed the generally held view, that 
increased TG2 levels appears protective to cancer cells and that decreased TG2 
levels are associated with poorer survival of cancer cells. This was done using retinoic 
acid to increase TG2 levels and cystamine to decrease TG2 levels. The results 
consistently support a role for TG2 in cell survival (figures 4.8 and 4.9). The findings 
reported here therefore suggest a potentially novel mechanism of action of cisplatin-
induced cytotoxicity in relation to apoptosis or protection of cells from cisplatin via 
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modulation of TG2 expression (sections 4.2.2-4.2.9), and possibly by direct inhibition 
of enzyme activity (section 4.2.10).  
Cellular uptake studies using DNC (which is a competitive inhibitor of TG2) showed 
that decreased TG2 levels increased uptake of fluorescent probe (presumably by 
endocytosis), both in HepG2 and CAKI2 cell lines (figures 3.3 and 3.5). This was also 
seen using a fluorescently-labelled analogue of cisplatin (figure 6.6). Western blot 
analysis confirmed that loss of TG2-L was consistent with these effects, as siRNA 
knockdown did not significantly affect TG2-S levels, which showed some traces of 
TG2-S in both cell lines (figure 6.5). This uncomplete removal of TG2-S explains the 
pattern of uptake of cisplatin in chemoresistant cells (figure 6.5B). Western blot 
analysis showed that cisplatin treatment caused loss of TG2-S from the plasma 
membrane and relocation to the cytoplasm (figure 6.3). This may explain the induction 
of apoptosis in these cells, as TG2-S is associated with proapoptotic activity (the 
reverse of TG2-L’s role) (Antonyak, et al., 2006). Interestingly, no such relocation was 
seen in chemoresistant cells, where TG2-S remained in the plasma membrane 
following cisplatin treatment (figure 6.3). These results indicate that the presence of 
TG2 isoforms in the plasma membrane of chemo-resistant cells may affect the 
trafficking of cisplatin, and therefore may also be responsible for driving cancer cells 
towards chemo-resistance. To the best of my knowledge, I believe this is the first time 
it has been shown that TG2 isoforms change their sub-cellular location upon cisplatin 
entry. The two isoforms identified in this study were not directly dissected by specific 
analysis, e.g., Mass spectrometric (MS)-analysis, but conclusions are aided by 
published data from other studies (Antonyak, et al., 2006; Tee, et al., 2010).          
Collectively, the results suggest that TG2 may act by blocking uptake of DNC and 
cisplatin in hepatocarcinoma cells (HepG2) and may possibly involved in other cell 
types. Unblocking of this activity via inhibitors may therefore offer a strategy for 
increasing susceptibility of these cells to chemotherapeutic drugs. Interestingly, 
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cystamine derivatives are well tolerated clinically (Fujisawa, et al., 2012) and may 
offer a route to cisplatin/cystamine co-treatment of patients with hepatocellular 
carcinoma. 
It is known from several studies that the reduced uptake of cisplatin in various 
cisplatin-resistant cells has been linked to various transporter proteins. These include 
ATP7B and ATP7A (Katano, et al., 2004; Safaei, et al., 2005), Claudin-4 (Yoshida, et 
al., 2011), TMEM205 (Shen, et al., 2010), and ABC transport proteins MRP1 and 
MRP2 (Kool, et al., 1997; Borst, et al., 2000) - suggesting important, but not 
necessarily exclusive, roles for such transporters during influx and efflux of drugs in 
drug-resistant cells. The current data suggest a reasonably strong connection 
between TG2 and cisplatin uptake, leading to an increase in cell death by apoptosis 
in tumour cells - but does not yet offer a mechanistic explanation. Thus, on the basis 
that TG2 substrate may contribute to the effects observed, TG2 substrates that had 
been modified by DNC during uptake experiments were immunoprecipitated and 
analysed by SDS-PAGE. The results show that a protein of approximately the same 
molecular weight as aldolase (46 kDa) was modified during DNC treatment (figure 
7.8). Increased expression of this glycolytic enzyme has been associated with cancer 
cells and it has previously been identified as a substrate for TG2 in HT29 colon cancer 
cells (Lee, et al., 1992). As cancer cells are essentially glycolytic in their energy 
production, it would be interesting if ATP-dependent endocytic events were modified 
(i.e. blocked) downstream by TG2 modification of a key glycolytic enzyme such as 
this. Also, other two DNC-labelled bands found were unknown to previously identified 
substrates, suggesting some new substrates of TG2 and these substrates may 
possibly suggest a connection between TG2 and cellular uptake of drugs.   
Finally, it may be significant that in vitro experiments presented here show that as 
well as affecting gene expression of TG2, cisplatin can directly inhibit TG2 (figure 
4.10). This suggests a secondary route to potentially blocking TG2 activities by 
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cisplatin and thus inducing cell death, by a hitherto undocumented mechanism. 
Therefore, the current study speculates that this inhibition of TG2 by cisplatin may be 
involved in the stimulation/regulation of other pro-apoptotic/pro-survival proteins 
involved in apoptotic/cell survival pathways in addition to its direct involvement, in 
apoptotic body formation in HepG2 cells (figure 8.1).  
 
 
Figure 8.1 Proposed mechanism of cisplatin-induced apoptosis or cell 
survival by TG2.  
In HepG2 cells, cisplatin inhibited the expression and activity of TG2. Once 
TG2 is inhibited, it may increase the expression of caspases and trigger 
apoptosis (Tatsukawa, et al., 2011). On the other hand, overexpression of 
TG2 by retinoic acid may inhibit caspases and thus protect cells from cisplatin 
toxicity.     
 
Several questions arise as a consequences of this work: 1) Is TG2 alone responsible 
for transport of cisplatin? Or 2) Does it regulate other drug transporters? These 
questions need further analysis.              
125 
 
8.2 Conclusions  
The induction of apoptosis in hepatocarcinoma cancer cells by cisplatin appears not 
only to be dependent on drug-dependent DNA modification, but may also be due to 
functional damage caused by this drug to known protein modulators of apoptosis, 
e.g., TG2. In vitro results from this study show that there may be some direct effect 
of cisplatin on TG2 activity, possibly caused by cisplatin competing for intracellular 
substrates at the active (lysyl) binding site of TG2. Collectively, these results may 
explain why increased TG2 expression in cancer cells contributes to the development 
of their resistance to chemotherapeutic drugs such as cisplatin; higher doses may be 
expected to be required to reduce TG2 expression to levels consistent with non-
resistance. These observations also support the contention that there may be 
potential for improving cisplatin-based cancer treatment by enhancing the 
effectiveness of patient-tolerable cisplatin doses, especially if cisplatin chemotherapy 
is combined with relatively non-toxic doses of specific TG2 inhibitors, such as DON 
compounds (6-diazo-5-oxo-L-norleucine containing peptides). Such treatment 
strategies for patients might also include avoidance of rich nutritional sources of 
retinoids, e.g., carrots, which have been counter-indicated in several epidemiological 
nutritional studies, where recipients of these supplements became more prone to 
development of cancer(s) than those consuming placebos (Omenn, et al., 1996). 
Collectively, these results indicate that the level and location of TG2 activity in 
hepatocellular carcinoma prevents or limits the entry of anti-cancer drugs, and thus 
inhibits apoptosis. Thus, TG2 may represent a novel biomarker and therapeutic target 
for overcoming the chemotherapeutic resistance of hepatocarcinoma.  
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8.3 Future work  
Several future studies are suggested from the findings of this thesis; these may 
include the following:  
 The investigation of cisplatin/TG2 interactions, including bioinformatic 
modelling to demonstrate the feasibility of binding of cisplatin at the catalytic 
site; 
 Experiments described herein (sections 4.2.6, 4.2.9 and 6.2.3) should be 
repeated using more specific inhibitors of TG2, e.g., DON compounds (6-
diazo-5-oxo-L-norleucine containing peptides); 
 The potential compensation by TG1 and other Tgases should be investigated 
in cell death, as this study detected induction of TG1 expression during cell 
death;  
 Given the protective effects of TG2 against cisplatin seen herein on high TG2 
expressing system like Hepatocarcinoma, it would be interesting to test to see 
if the same effects could be seen in low TG2 expressing systems; 
 It would be a large step forward to test to see if these cisplatin-resistant HepG2 
cells can survive as implants in mouse models (He, et al., 2015; Rao, et ., 
2016) and to compare the effects of modulation of TG2 expression on cellular 
uptake mechanisms as observed in this study;  
 It would be useful to investigate the effects of cisplatin on other modulators of 
apoptosis, e.g., caspases, both in vitro and in vivo in order to help further 
understand the mode of action of cisplatin on downstream elements of 
apoptotic pathways;   
 It would also be interesting to investigate the involvement of TG2 during 
cellular uptake of other anti-neoplastic/cisplatin drugs in HepG2/other cell 
lines, respectively;  
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 Identify the immunoprecipited protein in both parental and chemoresistance 
cells using MS-analysis, western blotting and endoproteinase digestion and 
investigate their link with TG2 in the mechanism of drug trafficking. This should 
help clarify whether TG2 alone is a drug transporter or it is just an 
activator/deactivator and/or blocker of other drug transporters;  
 
Collectively, such future studies will help to illustrate further the mechanisms involved 
in cancer development, and will help to develop novel strategies to design drugs and 
increase efficiency of cisplatin chemotherapy.  
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Appendix I: Supplementary data for chapter 4, 5 and 6 
 
Figure I.1 Effects of cisplatin on TG1 gene expression  
TG1 mRNA expression measured by RT-PCR. HepG2 cells were incubated 
with 0-16 µM cisplatin for 24 hours.  
 
 
 
 
Figure I.2 Confirmation of apoptosis by DNA fragmentation analysis.    
HepG2 cells were treated with 0-16 µM cisplatin for 24 hours. DNA was isolated and 
separated on 1.2% agarose gel electrophoresis.  
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Figure I.3 Apoptosis induction by cisplatin treatment after 48 hours of 
incubation.  
HepG2 cell were treated or not treated with 8 µM cisplatin for 48 hours. Apoptosis 
induction was analysed by flow cytometry using propidium iodide (PI) staining.  
 
 
Figure I.4 Effects of cisplatin on TG2 protein expression after 6 hours of 
treatment.   
HepG2 cells were treated with 0-16 µM cisplatin for 6 hours. TG2 protein expression 
was measured by Western blotting.  
 
 
 
 
 
Figure I.5 TG2 expression after retinoic acid treatment for 2 days.  
HepG2 cells were treated with 10 µM retinoic acid for 2 days. TG2 protein 
expression was measured by Western blotting.  
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Figure I.6 Comparison of glutathione-s-transferase (GST) expression in 
HepG2 and HepG2/cr cells.   
Western blot showing the bands for GST in HepG2 and HepG2/cr cells.  
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Appendix II: List of TG2 substrate proteins  
Substrate  Subcellular Localization  Reactive glu/lys  
40S ribosomal protein SA  Cytosol  - 
Acidic proline rich protein  Extracellular; enamel 
 pellicle in oral cavity 
- 
Aconitase  Mitochondria  - 
ACTH Plasma  - 
Actin(TG2) Cytoskeleton  Q41/K113 
Aldolase A  Cytosol  - 
Alpha lactalbumin(TG2) Extracellular; milk  Q54/K16,K93,K122 
Alpha synuclein  Cytosol  Q79,Q99/K80 
Alpha-2 macroglobulin 
receptor  
Plasma membrane  - 
Alpha-2 plasmin inhibitor Extracellular; plasma  Q2 
Alpha-2-HS-glycoprotein Extracellular; 
mineralized compartment of 
bone  
- 
Alpha-ketoglutarate 
dehydrogenase  
Mitochondrial matrix - 
Amyloid beta A4 peptide Extracellular; 
Cerebrospinal fluid  
Q15/K16,K28 
Androgen receptor  Nucleus  K311 
Angiocidin  Cytosol extracellular matrix  - 
Ankyrin Erythrocyte cytoskeleton - 
Annexin I  Cytosol; plasma membrane  Q19/K29 
Arginase I Cytosol  - 
AT-rich interactive 
domain-containing 
protein-1A 
Nucleus  Q82,Q84,Q98 
(Q465,Q467,Q481) 
Ataxin-1 Nucleus  - 
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ATP synthase  Mitochondrial inner 
membrane  
- 
Band 3 anion transport 
protein  
Erythrocyte membrane  Q30 
Band 4.1 protein  Erythrocyte cytoskeleton  - 
Bcr-Breakpoint cluster 
region  
Cytosol  - 
Beta casein  Extracellular; milk  Q167/Q182,Q194 
Beta endorphin  Extracellular; secreted  Q11/K29 
Beta tubulin(TG2) Cytoskeleton  - 
Beta-2-microglobulin Cell surface  - 
Betaine-homocysteine S-
methyltransferase 
Cytosol  Q384,Q385,Q392,Q393 
BiP protein  Endoplasmic reticulum 
lumen  
- 
Bone sialoprotein  Extracellular; 
mineralized compartment of 
bone 
- 
C-CAM  Plasma membrane  Q496,Q497 
C1 inhibitor Extracellular; plasma  Q453 
Calbindin  Extracellular; secreted 
signal molecule  
- 
Calpain Cytosol  - 
Caspase-3 Cytosol - 
Cathepsin D Cytosol - 
CD38 Plasma membrane  - 
Clathrin heavy chain Intracellular; vesicle 
membrane  
- 
Collagen(TG2) Cytosol/extracellular  III.-Q14 
VII.-Q2796,Q2800, 
       Q2805,Q2807 
Crystallin Cytoskeleton/plasma 
membrane, 
βB2-Q9,βB3-Q21, 
βA3-Q23/24/ K33,   
153 
 
cytosolic/nuclear 
localization  αB-K175 
Cyclic Thymosin beta 4  Cytoplasm  Q36/K16 
Cytochrome C Mitochondria  Q42 
Deoxyribonuclease ϒ Nucleus  - 
Dihydropyrimidinase-like 
2 protein  
Cytosol  - 
Dual leucine zipper-
bearing kinase(DLK) 
Cytosol/membrane 
associated  
- 
EGF receptor  Plasma membrane  - 
Elafin(TG2) Cornified envelope  Q2, Q59/K6 
Elongation factor 1α Cytosol  - 
Elongation factor 1ϒ Cytosol  - 
Enolase  Cytosol  - 
Envelope glycoprotein 
gp120 
HIV exterior membrane  Q265 
Envelope glycoprotein 
gp41 
HIV exterior membrane  Q51,Q52,Q66/K77 
Ephrin A  Plasma membrane, 
extracellular space  
- 
Eukaryotic intiation factor 
4F(eIF-4F) 
Cytosol  - 
Exendin 4  Excreted  K12,K27 
Ezrin-Radixin-Moesin 
binding phosphoprotein 
50 
Cytosol/plasma membrane  - 
F-box only protein  Cytosol  - 
Fatty acid synthase  Cytosol  - 
Fibrinogen alpha chain Extracellular; plasma  Q328,Q366/K148, 
K230,K303,K413 
Fibrinogen gamma chain Extracellular; plasma Q398/K406 
Fibronectin Extracellular; plasma Q3,Q32 
Filamin 1 Cytoskeleton  - 
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Fructose 1,6-
bisphosphatase 
Cytosol  - 
Galectin 3 Nuclear  Q47,Q56/K114 
Gliadin Vacuole  Q72 
Gliadoralin A Secreted  K60 
Glucagon Extracellular; plasma Q3,Q20 
Glutathione S-transferase Cytosol  Q51 
Glyceraldehyde-3-
phosphate 
dehydrogenase   
Mainly cytosolic associated 
to cytoskeleton and 
membranes, nucleus  
K191,K268,K331 
Hepatitis C virus core 
protein 
Hepatitis C virus  - 
Histamine Extracellular; secreted  - 
Histatin Extracellular; enamel 
pellicle in oral cavity  
- 
Histone H1 Nucleus  - 
Histone octamer  -H2A,  
                              -H2B,  
                              -H3,  
                              -H4 
Nuclear  H2A-Q24,Q104,Q112 
H2B-Q95,Q22/K116,K125 
H3-Q125,Q5,Q19 
H4-Q27,Q93 
HIV-1 aspartyl protease HIV virus  - 
Hsp 27 Plasma membrane, 
cytoskeletal element  
Q31,Q190/K209 
Hsp 60 Mitochondria  - 
Hsp70 Cytosol  - 
Hsp70/90 organizing 
protein 
Mitochondria  - 
Hsp 90 Cytosol  - 
Human clara-cell 10kDa 
protein 
Extracellular; secreted  - 
Huntingtin Cytosol  - 
Hyphal wall protein-1 Germ tube and true hyphae 
surface of C. albicans  
- 
155 
 
Ig kappa chain C region Extracellular; secreted  - 
Importin β1 subunit Cytosol, nuclear envelope  - 
Template: infobox Cytoskeleton  Q41 
Insulin Extracellular; plasma  Chain A-Q5,Q15 
Chain B-Q4 
Insulin-like growth factor-
binding protein-1 
Extracellular fluid  Q66,Q67 
Insulin-like growth factor-
binding protein-3 
Extracellular fluid  - 
Inter-alpha-inhibitor Extracellular space  HC1-Q8,Q319,Q468 
HC2-Q90,Q203,Q204,Q299, 
Q315,Q420,Q431,Q438 
Bikunin-Q74 
Lamin A, C Nuclear lamina  - 
Latent transforming 
growth factor beta 
binding protein 1 
Extracellular matrix  Q374 
Lipoprotein A Extracellular; 
plasma/extracellular space  
- 
Low-density lipoprotein 
receptor-related protein6 
Membrane, endoplasmic 
reticulum  
K1403 
Melittin Bee venom  Q25 
Microfibril-associated 
glycoprotein(MAGP) 
Extracellular matrix  Q20 
Midkine Extracellular, plasma  Q42,Q44,Q95/K63 
Myelin basic protein Myelin membrane  Q74,Q122,Q146,Q149 
Myosin Cytosol  - 
Neurofilament protein Neuronal cytoskeleton  - 
Neuropeptide ϒ Excreted  Q34 
NF-kappa-B inhibitor α Cytosol  Q266,Q267,Q313/ 
K21,K22,K177 
Nidogen Extracellular; basement 
membrane   
Q726 
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Nuclease sensitive 
element binding protein1 
Nucleus  - 
Nucleophosmin Nuclear  - 
Orexin B Excreted  Q8,Q12 
Osteonectin Extracellular  Q3,Q4 
Osteopontin  Extracellular; mineralized 
compartment of bone 
Q34,Q36 
Parkin Cytosol  K49 
Periphilin Nuclear membrane, 
cornified envelope 
- 
Periplakin Cornified envelope - 
Phosphoglycerate 
dehydrogenase 
Cytosol  - 
Phospholipase A2 Cytosol , venom Q4/K10 
Phosphorylase kinase Cytosol - 
Plasminogen Extracellular;secreted Q322/K298 
Plasminogen activator 
inhibitor-2 
Cytosol, plasma Q83,Q84,Q86 
Plasmodium falciparum 
liver stage antigen-1 
Cytosol  - 
Procarboxypeptidase B/U Extracellular; secreted  Q2,Q5,Q292 
Prohibitin Mitochondria  - 
Protein kinase C delta 
type 
Cytoplasm, cell membrane   Q545 
Protein synthesis 
initiation factor 5A 
Cytosol  K(Hypusine 50) 
RAP-α-2 macroglobulin 
related protein 
Cytosol  Q261 
Retinoblastoma protein Nucleus  - 
Rho associated, coiled 
coil, containing protein 
kinase 2 
Cytoskeleton  - 
RhoA Cytoskeleton  Q52,Q63,Q136 
S100 calcium-binding 
protein A10 
Cytosol, cornified envelope  Q4 
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S100 calcium binding 
protein A11 
Cytosol, keratinocyte 
cornified envelope  
Q102/K3 
S100 calcium-binding 
protein A7 
Cytosol, cornified envelope  Q5/K88 
Seminal vesicle secretory 
protein IV 
Extracellular; rat seminal 
fluid  
Q9,Q86/K2,K4, 
K59,K78,K79,K80 
Serotonin Extracellular; secreted 
signal molecule  
- 
SNAP-25 Plasma membrane  - 
SP-1 transcription factor Nucleus  - 
Spectrin Cytoskeleton, plasma 
membrane  
- 
Statherin Extracellular; enamel 
pellicle in oral cavity 
- 
Substance P Extracellular; secreted  Q5 
Suprabasin Cornified envelope  - 
Synapsin 1 Synaptic vesicle membrane  - 
Synapsin I Bound to synaptic vesicle 
membrane  
la-Q665,Q685 
T-complex protein 1ϵ 
subunit   
Cytosol  - 
Tau protein Cytoskeleton  Q6,Q88,Q124,Q244,QQ276, 
Q288,Q351,Q424/K24,K163, 
K174,K180,K190,K225,K234, 
K240,K383,K385 
Thymosin beta 4 Cytosol , plasma  Q23,Q36/K38 
Thyroglobulin Extracellular; follicle lumen  - 
Troponin Cytoskeleton  TnT-Q191 
TnI-K193 
Tumour rejection 
antigen1 
Endoplasmic reticulum 
lumen  
- 
Ubiquitin Cytosol  K29,K48 
Uteroglobin Extracellular; secreted  - 
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UV excision repair protein 
RAD23 homolog B 
Nucleus  - 
Valosin Nucleus, cytosol  - 
Vasoactive intestinal 
peptide 
Extracellular; secreted  Q16/K20,K21 
VEGFR-2 Plasma membrane, nucleus  - 
Vigilin Nucleus, cytosol  - 
Vimentin Lens cytoskeleton  Q453,Q460/ 
K97,K104,K294,K439 
Vitronectin Cytoskeleton  Q93 
Y-box binding protein Cytoplasm, Nucleus  - 
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Appendix III: General solutions    
1) SDS-PAGE  
Laemmli 2x sample buffer:  
4% SDS 
10% 2-mercaptoethanol  
20% glycerol  
0.004% bromophenol blue  
0.125 M Tris-HCl, pH 6.8  
 
1x MOPS Buffer: 
20 mM 4-morpholinopropanesulfonic acid, pH 7.0 
8 mM sodium acetate  
1 mM EDTA  
 
1x MES Buffer: 
20mM 2-morpholinoethanesulfonic acid, pH 7.0 
8 mM sodium acetate  
1mM EDTA  
 
1x Tris-Glycine buffer:  
25 mM Tris-Base, pH 8.3  
192 mM Glycine  
0.1% SDS 
 
 
Coomassie stain: 
0.25% coomassie brilliant blue R-250 in a mixture of water:acetic acid:methanol 
(40:10:50) 
 
Coomassie stain remover: 
A mixture of 60% water, 10% acetic acid, and 30% methanol.  
  
2) Western blotting  
 
1x TBS:  
50 mM Tris Base, pH 7.6 
0.20 M NaCl   
 
Transfer Buffer: 
25 mM Tris  
192 mM glycine  
20% Methanol 
 
1x TBST: 
1 mL Tween-20 in 1 lit 1x TBS  
 
1x PBS: 
10 mM Na2HPO4, pH 7.4 
2 mM KH2PO4 
137 mM NaCl  
2.7 mM KCl 
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Blocking reagent:  
1) 5% non-fat dry milk in TBST 
2) 3-5% BSA in TBST   
 
Ponceau S Red: 
0.5 g in 100 mL 1% acetic acid  
Stain removal- 10% isopropyl alcohol/10% acetic acid 
Steps: stain blot for 2-5 min, rinse in water, if not then in stain removal. 
 
Antibody removal solution:  
0.5 M Tris-Hcl, pH 6.7, 0.7% β-mercaptoethanol, 10% SDS 
Steps: incubate blot in antibody removal solution for 15 minutes at 65o C, then wash 
membrane with 1x PBS or TBST for 2 hours to overnight, air dried and then reuse.   
 
 
3) Agarose gel electrophoresis  
 
Agarose gel:  
1.2% agarose in 1x TBE buffer 
  
1x TBE: 
45 mM Tris-base 
45 mM boric acid 
2 mM EDTA, pH 8.0 
4) Flow cytometry  
 
Binding buffer:  
0.1 M HEPES, pH 7.4 
1.4 M NaCl;  
25 mM CaCl2  
